Improved production of split antibodies

By incorporating specific mutations in split antibodies to prevent light chain association, the production of split antibodies is optimized, addressing the issue of unwanted side products and improving yield and manufacturability.

WO2026238433A1PCT designated stage Publication Date: 2026-11-19VERAXA BIOTECH GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/062314
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-10
Filing Date
2026-04-29
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

The production of split antibodies, particularly T cell engagers, is hindered by unwanted side products that decrease the monomer content and complicate manufacturability, leading to low volumetric yield and high production costs.

Method used

Optimize the pairing of polypeptides in split antibodies by introducing specific mutations, such as amino acid substitutions at position 86 (e.g., alanine) or domain exchanges, to prevent unwanted light chain association, thereby increasing the monomeric yield and simplifying purification.

Benefits of technology

The mutations significantly reduce light chain association, enhancing the monomeric yield and improving the manufacturability of split antibodies, ensuring higher purity and lower production costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026062314_19112026_PF_FP_ABST
    Figure EP2026062314_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates to antibody-based molecules which are composed of two half-molecules which associate with each other to form a full molecule. Formation of the full molecules is often hampered by association of the variable light chain to the incorrect variable heavy chain The present invention identified approaches to avoid such mispairing.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] IMPROVED PRODUCTION OF SPLIT ANTIBODIES

[0002] FIELD OF THE INVENTION

[0003] The present disclosure relates to antibody-based molecules which are composed of two halfmolecules which associate with each other to form a full molecule. Formation of the full molecules is often hampered by association of the variable light chain to the incorrect variable heavy chain The present invention identified approaches to avoid such mispairing.

[0004] BACKGROUND OF THE INVENTION

[0005] T cell engaging antibodies are a class of bispecific antibodies designed to redirect polyclonal T cells towards tumor cells. By simultaneous binding of tumor associated antigens (TAA) on the target cell and a receptor, e.g. CD3, on the T cell (effector cell) a crosslinking is achieved that leads to T cell activation, proliferation and cytokine release which results in T cell dependent cytotoxicity towards the target cell.

[0006] Most clinical approved T cell engagers show promising efficacy and durable responses in hematologic malignancies, such as Blinatumumab (CD19 x CD3) in acute lymphoblastic leukemia (ALL) or Teclistamab (BCMAx CD3) in multiple myeloma. Nevertheless, even in solid cancer promising response rates with manageable safety profiles could be achieved with Tebentafusp (gplOO xCD3) for uveal melanoma orTarlatamab (DLL3 x CD3) in Small Cell Lung Cancer (SCLC).

[0007] Despite these achievements, many clinical trials and research therapies in solid cancers have had to be discontinued due to various problems faced by conventional T-cell engagers. In particular, the lack of tumor-specific targets limits the broad application of this potent therapeutic class.

[0008] The high therapeutic potential combined with the safety liabilities of T cell engagers led to the development of T cell engagers with tumor restricted activity achieved by on-cell assembly approaches that mediate specificity gain by logic AND-gates, such as the hemibody technology which was pioneered by Stuhler et al (Nat Commun (2019) 26; 10( 1) :5387).

[0009] In this concept, the active CD3 binder is split into two halves, namely the VH and VL, which alone can neither bind, nor activate T cells. The single domains (VH or VL) were fused to two separate targeting moieties (TAA1, TAA2). These precursor molecules can bind tumor cells, however, T cell bindingremains inactive. Upon co-localization on dual positive (TAA1+TAA2) tumor cells the split CD3 binder gets restored, and the T cell activation induced. By this logic AND-gate, the T cell killing capacity is meant to be unleashed specifically at the tumor with limited activity in healthy (single TAA positive) tissue. Thereby, the therapeutic window and hence the amount of safely druggable targets, especially in solid cancer, is increased. The concept is depicted in Figure 1.

[0010] During the production of these split molecules, however, certain unwanted side products appear and decrease the desired monomer content, and hence the volumetric yield. Finally, the laborious isolation of the clean monomeric fraction translates into a complex and costly manufacturability.

[0011] Thus, there remains a need for optimizing the precursor molecules by protein engineering to force the correct pairing of the polypeptides, thereby increasing the monomeric yield of the desired protein. The present invention provides solutions to abolish the formation of unwanted side products during the expression of split antibodies which ultimately translates into better manufacturability.

[0012] SUMMARY OF THE INVENTION

[0013] In certain embodiments, the present invention relates to a molecule comprising

[0014] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0015] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0016] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein

[0017] i) said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 with an amino acid substitution at position L45 (according Chothia) and a variable light chain of SEQ ID No.2, ii) the variable light chain of said first antigen binding domain has a mutation at position 86 (according to Chothia), preferably wherein said mutation is a mutation to alanine, or

[0018] ill) in said first antigen binding domain at least the VH domain and VL domain are replaced by each other. In certain embodiments, said variable heavy chain of the third antigen binding domain and said variable light chain of the third antigen binding domain associate with each other. In certain embodiments, said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 76or 77 and a variable light chain of SEQ ID No. 2. In certain embodiments, the variable light chain of said first antigen binding domain has a mutation to alanine at position 86 (according to Chothia), and said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2. In certain embodiments, in said first antigen binding domain the variable light chain is replaced by the variable heavy chain of said first antigen binding domain and the constant light chain domain CL is replaced by the constant heavy chain domain CHI of said first antigen binding domain, and the variable heavy chain is replaced by the variable light chain first of said antigen binding domain and the constant heavy chain domain CHI is replaced by the constant light chain domain CL of said first antigen binding domain. In certain embodiments, in said first antigen binding domain the variable light chain is replaced by the variable heavy chain of said first antigen binding domain, and the variable heavy chain is replaced by the variable light chain first of said antigen binding domain. In certain embodiments, said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2. In certain embodiments, the present invention relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0019] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein

[0020] i) said variable heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 with an amino acid substitution at position L45 (according Chothia),

[0021] ii) the variable light chain of said first antigen binding domain has a mutation to alanine at position 86 (according to Chothia), or

[0022] ill) in said first antigen binding domain at least the VH domain and VL domain are replaced by each other. In certain embodiments, said heavy chain of said third antigen binding domain comprises a variable heavy chain ofSEQID No. 76 or 77. In certain embodiments, the variable light chain of said first antigen binding domain has a mutation to alanine at position 86 (according to Chothia) and wherein said heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80. In certain embodiments, in said first antigen binding domain the variable light chain is replaced by the variable heavy chain of said first antigen binding domain and the constant light chain domain CL is replaced by the constant heavy chain domain CHI of said first antigen binding domain, and the variable heavy chain is replaced by the variable light chain first of said antigen binding domain and the constant heavy chain domain CHI is replaced by the constant light chain domain CL of said first antigen binding domain. In certain embodiments, in said first antigen binding domain the variable light chain is replaced by the variable heavy chain of said first antigenbinding domain, and the variable heavy chain is replaced by the variable light chain first of said antigen binding domain. In certain embodiments, said heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80.

[0023] In certain embodiments, the present invention relates to a nucleic acid molecule or a nucleic acid composition comprising a nucleic acid sequence or a plurality of nucleic acid sequences encoding a molecule or a half-molecule according as defined herein above.

[0024] In certain embodiments, the present invention relates to a molecule or a half-molecule as defined herein above for use in medicine. In certain embodiments, said used in medicine is the treatment of a cancer, an inflammatory disease or an autoimmune diseases.

[0025] In certain embodiments, the present invention relates to a molecule comprising

[0026] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0027] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0028] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein the variable light chain of said first antigen binding domain has a mutation at position 86 (according to Chothia).

[0029] In certain embodiments, the variable light chain of said first antigen binding domain has an amino acid at position 86 (according to Chothia) selected from methionine, leucine, lysine, valine, alanine, serine, proline, glutamine, arginine, glutamic acid, threonine, asparagine, aspartic acid, cysteine, histidine and glycine. In certain embodiments, the variable light chain of said first antigen binding domain has an amino acid at position 86 (according to Chothia) selected from alanine, serine, proline, glutamine, arginine, glutamic acid, threonine, asparagine, aspartic acid, cysteine, histidine and glycine. In certain embodiments, the variable light chain of said first antigen binding domain has an amino acid at position 86 (according to Chothia) selected from alanine, serine, proline, glutamine, arginine and glutamic acid. In certain embodiments, the variable light chain of said first antigen binding domain has a mutation to alanine, serine, proline, glutamine, arginine or glutamic acid at position 86 (according to Chothia), and said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2.

[0030] In certain embodiments, the present invention relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein the variable light chain of said first antigen binding domain an amino acid at position 86 (according to Chothia) selected from methionine, leucine, lysine, valine, alanine, serine, proline, glutamine, arginine, glutamic acid, threonine, asparagine, aspartic acid, cysteine, histidine and glycine. In certain embodiments, the variable light chain of said first antigen binding domain has an amino acid at position 86 (according to Chothia) selected from alanine, serine, proline, glutamine, arginine, glutamic acid, threonine, asparagine, aspartic acid, cysteine, histidine and glycine. In certain embodiments, the variable light chain of said first antigen binding domain has an amino acid at position 86 (according to Chothia) selected from alanine, serine, proline, glutamine, arginine and glutamic acid.

[0031] In certain embodiments, the present invention relates to a nucleic acid molecule or a nucleic acid composition comprising a nucleic acid sequence or a plurality of nucleic acid sequences encoding aforementioned molecules or half-molecules.

[0032] In certain embodiments, the present invention relates to aforementioned molecules or half-molecules for use in medicine. In certain embodiments, said used in medicine is the treatment of a cancer, an inflammatory disease or an autoimmune diseases.

[0033] In certain embodiments, the present invention relates to a method of improving a molecule comprising a) providing a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain, wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0034] b) substituting the amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain to a methionine, leucine, lysine, valine, alanine, serine, proline, glutamine, arginine, glutamic acid, threonine, asparagine, aspartic acid, cysteine, histidine or glycine.

[0035] In certain embodiments, said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to alanine, serine, proline, glutamine, arginine, glutamic acid, threonine, asparagine, aspartic acid, cysteine, histidine or glycine. In certain embodiments, said variable light chain of the first antigen binding domain provided in step a) has a tyrosine at position 86 (according to Chothia).DESCRIPTION OF THE FIGURES

[0036] Figure 1 shows a schematic illustration of exemplary BiTAC precursor molecules according to the invention. Figure 1A: Two BiTAC precursors, each comprising one half of a split anti CD3 Fv, a targeting moiety for the binding of TAA and an Fc backbone for half-life extension. Circles in the Fc region indicate modifications to promote Fc heterodimerization following the knob-into-hole principle. Figure IB: Upon co-localization on dual TAA positive target cells and high local concentration of the two precursors, a CD3 binder restoration leads to the crosslinking and activation of polyclonal T cells. This artificial immune synapse formation triggers T cell-dependent cytotoxicity towards the target cell. Figure 2 shows a schematic illustration of a side product that appears during the expression of a BiTAC precursor molecule and data supporting this finding. Figure 2A: The BiTAC precursor carrying the VH of the CD3 binder is affected by an additional non-covalent light chain association at the unpaired UCHT Prime VH which decreases the monomer content and complicates the purification process. Figure 2B shows the results of a CE-SDS under non-reduced conditions, in which both the monomeric molecule and the additional light chain (black arrow) is present.

[0037] Figure 3 shows a schematic illustration of the light chain association to the split antibody carrying the WT sequence (left) and the single point mutations that abolish the light chain association to the unpaired VH. The mutations can be either incorporated in the VL of the target binder or the VH of the split CD3 binder. The most effective mutations are shown on the right.

[0038] Figure 4 shows the effect of the Y86A mutation in comparison to the WT in BiTAC precursor molecules targeting HER2. In Figure 4A, the LC association is clearly visible in the WT version by an additional peak in the CE-SDS profile under non-reduced conditions (black arrow). Figure 4B shows that the introduction of the Y86A mutation significantly reduces the LC association (grey arrow).

[0039] Figure 5 shows the significantly reduced amount of LC association when using the L45R mutation in the CD3 VH of a BiTAC precursor molecule targeting HER2.

[0040] Figure 6 shows the effect of the Y86A mutation in comparison to the WT in BiTAC precursor molecules targeting CD38. In Figure 5A, the LC association is clearly visible in the WT version by an additional peak in the CE-SDS profile under non-reduced conditions (black arrow). Figure 6B shows that the introduction of the Y86A mutation significantly reduces the LC association.

[0041] Figure 7 shows the significantly reduced amount of LC association when using the L45A mutation in the CD3 VH of a BiTAC precursor molecule targeting CD38 compared to the WT version (Figure 6)Figure 8: Binding of BiTAC precursors according to the present invention either with the WT sequence or the VL-optimized Y86A derivatives. Figure 8A shows the binding of a HER2-targeting BiTAC precursor with either the WT sequences or the Y86A mutation to SK-BR-3 cells (HER2 positive). Figure 8B shows the binding of a CD38-targeting BiTAC precursor carrying either the WT sequences or the Y86A mutation to MM. IS cells (CD38 positive). Antibody derivatives were incubated in combination with target cells at the indicated concentrations for 1 hour on ice. Bound molecules were stained with a fluorescence-labelled secondary antibody and analyzed by flow cytometry.

[0042] Figure 9: Binding of BiTAC precursors according to the present invention either with the WT sequence or the mutation at position L45 in the UCHT Prime VH. Figure 9A shows the binding of a HER2-targeting BiTAC precursor carrying either the WT sequences or the L45R mutation to SK-BR-3 cells (HER2 positive). Figure 9B shows the binding of a CD38-targeting BiTAC precursor carrying either the WT sequences or the L45A mutation to MM. IS cells (CD38 positive). Antibody derivatives were incubated in combination with target cells at the indicated concentrations for 1 hour on ice. Bound molecules were stained with a fluorescence-labelled secondary antibody and analyzed by flow cytometry. Figure 10 shows the tumor cell killing of the breast cancer cell line SK-BR-3 (HER2 positive, EpCAM positive) or myeloma cell line MM. IS (CD38 positive, SLAMF7 positive) with pan T cells from a healthy human donor when treated with the BiTAC precursor molecules with the respective specificities (HER / EpCAM or CD38 / SLAMF7). Figure 10A shows the HER2 targeting BiTAC either with the WT sequence or the Y86A mutation to abolish LC association in combination with the EpCAM-targeted counterpart. Figure 10B shows the CD38 targeting BiTAC either with the WT sequence or the Y86A mutation to abolish LC association in combination with the SLAMF7-targeted counterpart. Tumor cell killing was measured for SK-BR-3 cells by quantification of Lactate dehydrogenase (LDH) in the supernatant after 48 hours and for MM. IS cells by a cytometry-based readout after 24h

[0043] Figure 11: shows the tumor cell killing of the breast cancer cell line SK-BR-3 (HER2 positive, EpCAM positive) or myeloma cell line MM. IS (CD38 positive, SLAMF7 positive) with pan T cells from a healthy human donor when treated with the BiTAC precursor molecules with the respective specificities (HER / EpCAM or CD38 / SLAMF7). Figure 11A shows the HER2 targeting BiTAC either with the WT sequence or the L45R mutation to abolish LC association in combination with the EpCAM-targeted counterpart. Figure 11B shows the CD38 targeting BiTAC either with the WT sequence or the L45A mutation to abolish LC association in combination with the SLAMF7-targeted counterpart. Tumor cell killing was measured for SK-BR-3 cells by quantification of Lactate dehydrogenase (LDH) in the supernatant after 48 hours and for MM. IS cells by a cytometry-based readout after 24h.Figure 12 shows a schematic illustration of the LC association to the split antibody carrying the WT sequence (left) and an alternative strategy to abolish LC association on the right. Here, the VH and VL of the target-binder Fv are exchanged. The generated short VH-CL polypeptide does not associate with the split CD3 VH at the C-terminus.

[0044] Figure 13 shows the effect of the VH / VLexchange in the targeting Fab in comparison to the WT domain orientation. In Figure 13A, the LC association is clearly visible by an additional peak in the CE-SDS profile under non-reduced conditions (black arrow) in the natural domain orientation. Figure 13B shows that the domain exchange significantly reduces the LC association (grey arrow).

[0045] Figure 14 shows the effect of the VH / VLexchange in the targeting Fab in comparison to the WT domain orientation regarding cell binding and cytotoxicity. Figure 14A: Binding of BiTAC precursors according to the present invention either with the WT sequence or the VH / VL exchanged derivatives to SK-BR-3 (HER2 positive). Antibody derivatives were incubated in combination with target cells at the indicated concentrations for 1 hour on ice. Bound molecules were stained with a fluorescence-labelled secondary antibody and analyzed by flow cytometry. Figure 14B shows the tumor cell killing of the breast cancer cell line SK-BR-3 (HER2 positive, EpCAM positive) with pan T cells from a healthy human donor when treated with the BiTAC precursor molecules targeting HER2 and EpCAM. The HER2 targeting BiTAC carries either the WT domain orientation or the VH / VL exchanged geometry respectively. Tumor cell killing was measured by quantification of Lactate dehydrogenase (LDH) in the supernatant after 48 hours.

[0046] Figure 15 shows the effect of the Y86A mutation in comparison to the WTin BiTAC precursor molecules targeting HER2. In contrast to the previous figures, the tested molecule contains the variable region of an alternative CD3 binder, namely SP34. In Figure 15A, the LC association is clearly visible in the WT version by an additional peak in the CE-SDS profile under non-reduced conditions (arrow). Figure 15B shows that the introduction of the Y86A mutation significantly reduces the LC association.

[0047] Figure 16 shows a Venn diagram with properties of amino acids. Effects of a substitution of Y86 to the indicated amino acids on LC association is indicated.

[0048] Figure 17 shows that the additional variants of Example 2.3 do not affect cell binding.

[0049] Figure 18 shows the frequency of occurrence of the 20 natural amino acids at Chothia position 86 of the antibody variable light chain.DEFINITIONS

[0050] The term "antigen binding domain" and "targeting moiety" are used herein interchangeably and refer to a polypeptide-based binding molecule that specifically binds to an antigen such as a tumor associated antigen. The term includes antibodies, antibody fragments, antibody-based and nonantibody based binding molecules.

[0051] The term "antibody" as used herein refers to a protein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, which interacts with an antigen. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CHI, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FR's arranged from amino-terminus to carboxyterminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system. The term "antibody" includes for example, monoclonal antibodies, human antibodies, humanized antibodies, camelised antibodies and chimeric antibodies. The antibodies can be of any isotype (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., Igd , lgG2, lgG3, lgG4, IgAl and lgA2) or subclass. Both the light and heavy chains are divided into regions of structural and functional homology.

[0052] The term "antibody fragment", as used herein, refers to one or more portions of an antibody that retain the ability to specifically interact with (e.g., by binding, steric hindrance, stabilizing spatial distribution) an antigen. Examples of binding fragments include, but are not limited to, a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; a F(ab)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the VH and CHI domains; a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; a dAb fragment (Ward et al., (1989) Nature 341 :544-546), which consists of a VH domain; and an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, usingrecombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al., (1988) Science 242:423-426; and Huston et al., (1988) Proc. Natl. Acad. Sci. 85:5879-5883). Such single chain antibodies are also intended to be encompassed within the term "antibody fragment". These antibody fragments are obtained using conventional techniques known to those of skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies. Antibody fragments can also be incorporated into single domain antibodies, maxibodies, minibodies, intrabodies, diabodies, triabodies, tetrabodies, v-NAR and bis-scFv (see, e.g., Hollinger and Hudson, (2005) Nature Biotechnology 23:1 126-1 136). Antibody fragments can be grafted into scaffolds based on polypeptides such as Fibronectin type III (Fn3) (see U.S. Pat. No. 6,703,199, which describes fibronectin polypeptide monobodies). Antibody fragments can be incorporated into single chain molecules comprising a pair of tandem Fv segments (VH-CH1 -VH-CH1 ) which, together with complementary light chain polypeptides, form a pair of antigen-binding sites (Zapata et al., (1995) Protein Eng. 8: 1057-1062; and U.S. Pat. No. 5,641 ,870).

[0053] The structures and locations of immunoglobulin variable domains, e.g., CDRs, may be defined using well known numbering schemes, e.g., the Kabat numbering scheme, the Chothia numbering scheme, or a combination of Kabat and Chothia (see, e.g. Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services (1991 ), eds. Kabat et al.; Lazikani et al., (1997) J. Mol. Bio.

[0054] 273:927-948); Kabat et al., (1991) Sequences of Proteins of Immunological Interest, 5th edit., NIH Publication no. 91-3242 U.S. Department of Health and Human Services; Chothia et al., (1987) J. Mol. Biol. 196:901 -917; Chothia et al., (1989) Nature 342:877-883; and Al-Lazikani et al., (1997) J. Mol. Biol.

[0055] 273:927-948; Annals of the New York Academy of Sciences, 764, 47-49 (1995); Nucleic Acids Research, 25, 206-211 (1997).

[0056] A "human antibody" or "human antibody fragment", as used herein, is an antibody and antibody fragment having variable regions in which both the framework and CDR regions are from sequences of human origin. Human antibodies can also be isolated from synthetic libraries or from transgenic mice (e.g. Xenomouse, OmniMouse, Harbour Mouse, ATX-Gx Mouse, Trianni Mouse) provided the respective system yield in antibodies having variable regions in which both the framework and CDR regions are derived from sequences of human origin. Furthermore, if the antibody contains a constant region, the constant region also is derived from such sequences. Human origin includes, e.g., human germline sequences, or mutated versions of human germline sequences or antibody containing consensus framework sequences derived from human framework sequences analysis, for example, as described in Knappik et al., (2000) J Mol Biol 296:57-86).A "humanized antibody" or "humanized antibody fragment" is defined herein as an antibody molecule, which has constant antibody regions derived from sequences of human origin and the variable antibody regions or parts thereof or only the CDRs are derived from another species. For example, a humanized antibody can be CDR-grafted, wherein the CDRs of the variable domain are from a non-human origin, while one or more frameworks of the variable domain are of human origin and the constant domain (if any) is of human origin.

[0057] The term "chimeric antibody" or "chimeric antibody fragment" is defined herein as an antibody molecule, which has constant antibody regions derived from, or corresponding to, sequences found in one species and variable antibody regions derived from another species. Preferably, the constant antibody regions are derived from, or corresponding to, sequences found in humans, and the variable antibody regions (e.g. VH, VL, CDR or FR regions) are derived from sequences found in a non-human animal, e.g. a mouse, rat, rabbit or hamster.

[0058] The term "isolated antibody" or "isolated antibody fragment" refers to an antibody or antibody fragment that is substantially free of other antibodies or antibody fragments having different antigenic specificities. Moreover, an isolated antibody or antibody fragment may be substantially free of other cellular material and / or chemicals. Thus, in some aspects, antibodies provided are isolated antibodies, which have been separated from antibodies with a different specificity. An isolated antibody may be a monoclonal antibody. An isolated antibody may be a recombinant monoclonal antibody. An isolated antibody that specifically binds to an epitope, isoform or variant of a target may, however, have crossreactivity to other related antigens, e.g., from other species (e.g., species homologs).

[0059] The term "recombinant antibody" or "recombinant antibody fragment", as used herein, includes all antibodies or antibody fragment that are prepared, expressed, created or segregated by means not existing in nature. For example, antibodies isolated from a host cell transformed to express the antibody, antibodies selected and isolated from a recombinant, combinatorial human antibody library, and antibodies prepared, expressed, created or isolated by any other means that involve splicing of all or a portion of a human immunoglobulin gene, sequences to other DNA sequences or antibodies isolated from an animal (e.g., a mouse) that is transgenic or transchromosomal for human immunoglobulin genes or a hybridoma prepared therefrom. Preferably, such recombinant antibodies have variable regions in which the framework and CDR regions are derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies can be subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VHand VL sequences, may not naturally exist within the human antibody germline repertoire in vivo. A recombinant antibody may be a monoclonal antibody.

[0060] The term "BiTAC", as used herein, refers to a intermolecular complex comprising two halfmolecules, wherein each of the half-molecules comprises an antigen binding domain that specifically binds to a tumor associated antigen and a heavy chain variable region or a light chain variable region of a binding domain that specifically binds to a third antigen, such as CD3. If the first half-molecule comprises a heavy chain variable region of a binding domain that specifically binds to a third antigen, such as CD3, then the second half-molecule comprises a light chain variable region of the binding domain that specifically binds to the third antigen. If the first half-molecule comprises a light chain variable region of a binding domain that specifically binds to a third antigen, such as CD3, then the second half-molecule comprises a heavy chain variable region of the binding domain that specifically binds to the third antigen. The heavy chain variable region of the binding domain that specifically binds to the third antigen is capable form a functional binding domain with the light chain variable region of the binding domain that specifically binds to the third antigen, such as CD3..

[0061] The terms "BiTAC precursor", "BiTAC precursor molecule" or "hemibody" as used interchangeably herein and refer to one of said two half-molecules that form a BiTAC.

[0062] As used herein, an antibody "binds specifically to", "specifically binds to", is "specific to / for" or "specifically recognizes" an antigen, such as human CD45, if such antibody is able to discriminate between such antigen and one or more reference antigen(s), since binding specificity is not an absolute, but a relative property. For example, a standard ELISA assay or standard flow cytometry assay can be carried out. The scoring may be carried out by standard color development (e.g. secondary antibody with horseradish peroxide and tetramethyl benzidine with hydrogen peroxide) or by binding of a secondary antibody labeled with PE or another dye or marker. The reaction in certain wells is scored by the optical density (OD), for example, at 450 nm or by mean or median fluorescence intensity (MFI) in flow cytometry. Typical background (=negative reaction) may be 0.1 OD; typical positive reaction may be 1 OD. Background and positive reaction MFI are highly dependent on instrument settings. The difference positive / negative can be more than 10-fold. Typically, determination of binding specificity is performed by using not a single reference antigen, but a set of about three to five unrelated antigens, such as milk powder, BSA, transferrin or the like. For flow cytometry various antigen-negative cells can be used. An antibody that specifically binds to an antigen may however have cross-reactivity to the respective orthologous antigen from other species (e.g., species homologs). In certain embodiments such cross-reactivity to an orthologous antigen is even preferred.The term "CrossMab" as used herein refers to antigen binding domains with an inversion of all or parts of the VH-CH1 domains and the VL-CL domains.. For example, such binding domain comprises a VH domain linked to a CL domain and a VL domain linked to a CHI domain. CrossMab are for example described in WO 2009 / 080253 and Schaefer, W. et al, PNAS, 108 (2011) 11187-1191. In some instances, the antigen binding domain is an antibody or comprises or consists of a Fab, a Fv, a Fab', a scFv, a CrossMAb or a VHH covalently linked to a Fc domain, preferably an IgG Fc domain such as described herein. Not all known CrossMab formats are useful in the context of the present invention. To be used with the present invention, CrossMab formats are used that have an inversions of at least the VH and the VL domain, i.e. with or with an inversion of the C-terminal CHI and CL domains.

[0063] The term "internalizing" as used herein, refers to an antibody or antigen-binding fragment that is capable of being taken through the cell's lipid bilayer membrane to an internal compartment (i.e., "internalized") upon binding to the cell, such as into a degradative compartment in the cell. Antibodies and antibody fragments may for example be taken into the cell via receptor-mediated endocytosis.

[0064] As used herein, the term "affinity" refers to the strength of interaction between the polypeptide and its target at a single site. Within each site, the binding region of the polypeptide interacts through weak non-covalent forces with its target at numerous sites; the more interactions, the stronger the affinity.

[0065] The terms "knob into hole", "knob-into-hole" and "KiH" as used herein, refer to engineering the CH3 domain of antibody Fc region to create either a "knob" or a "hole" in each heavy chain to promote heterodimerization. Generally, a "knob" is created by replacing T366 with a bulky residue W on one heavy chain, and the corresponding "hole" is made by triple mutations of T366S, L368A and Y407V on the other heavy chain. The knob-into-hole structure may comprise other substitutions, as familiar in the art.

[0066] The term "antigen" as used herein refers to an protein or polypeptide comprising an epitope which is recognized by an antigen binding domain, such as an antibody or antibody fragment. The present invention relates to a pair of two antibodies or antibody fragments which bind to a first and a second antigen. The first and the second antigen recognized by these antibodies are preferably different antigens. This is important in the context of the avoidance of off-target toxicities. Nevertheless, if the target antigen is highly specific for cancerous tissues or cells, the first and the second antigen recognized by the two antibodies may principally also be the same antigen.

[0067] The terms "tumor associated antigen", "TAA" and "tumor antigen" are used interchangeably herein and refer to antigens that are presented on tumor cells. These antigens can be presentedon the cell surface with an extracellular part, which is often combined with a transmembrane and cytoplasmic part of the molecule. These antigens can sometimes be presented only by tumor cells and never by the normal ones. Tumor antigens can be exclusively expressed on tumor cells or might represent a tumor specific mutation compared to normal cells. In this case, they are called tumorspecific antigens. More common are antigens that are presented by tumor cells and normal cells, and they are called tumor-associated antigens. These tumor-associated antigens can be overexpressed compared to normal cells or are accessible for antibody binding in tumor cells due to the less compact structure of the tumor tissue compared to normal tissue. Non-limiting examples of tumor antigens include HER2, EpCAM, CD19, MSLN, DLL3, FLT3, EGFR, CD33, CD38, MUC17, CLDN18.2, CDH3, CD70, BCMA, PSMA, CEACAM5, HER3, STEAP-1, TROP-2, NECTIN-4, B7-H3, B7-H4, MUC16, FOLR1, CD200, CLDN6, GPRC5D, EGFRviii, MUC1 and 5T4.

[0068] The term "epitope" includes any proteinaceous region which is specifically recognized by an antibody or antibody fragment thereof or otherwise interacts with a molecule. Generally, epitopes are of chemically active surface groupings of molecules such as amino acids or carbohydrate or sugar side chains and generally may have specific three-dimensional structural characteristics, as well as specific charge characteristics. As will be appreciated by one of skill in the art, practically anything to which an antibody can specifically bind could be an epitope.

[0069] The terms "ADC" and "antibody drug conjugate" as used herein refer to a conjugate that includes (a) an antibody or an antibody fragment and (b) another moiety that is linked to said antibody or antibody fragment. The other moiety is typically referred to as "payload". Said payload is classically a toxic payload, i.e. a compound that kills or otherwise harms the cell after internalization of the ADC. The payload may however also be of other nature. For example, and as used within the spirit of the present invention, said antibody may also be a prodrug or an activator. In the present invention one antibody or antibody fragment is conjugated to a prodrug and the second antibody or antibody fragment is conjugated to an activator.

[0070] "Compositions" or of the present disclosure may be used for therapeutic or prophylactic applications. The present disclosure, therefore, includes a pharmaceutical composition containing a pair of antibodies or antibody fragments as disclosed herein and a pharmaceutically acceptable carrier or excipient therefore. In a related aspect, the present disclosure provides a method for treating inflammatory diseases, autoimmune diseases, hematologic malignancies and potentially other diseases. Such method contains the steps of administering to a subject in need thereof an effective amount of the pharmaceutical composition that contains the antibodies or antibody fragments as described herein.The present disclosure provides therapeutic methods comprising the administration of a therapeutically effective amount of an antibody or antibody fragment as disclosed herein to a subject in need of such treatment. A "therapeutically effective amount" or "effective amount", as used herein, refers to the amount of the antibodies necessary to elicit the desired biological response. In accordance with the subject disclosure, the therapeutic effective amount is the amount of antibodies necessary to treat and / or prevent a disease.

[0071] "Administered" or "administration" includes but is not limited to delivery of a drug by an injectable form, such as, for example, an intravenous, intramuscular, intradermal or subcutaneous route or mucosal route, for example, as a nasal spray or aerosol for inhalation or as an ingestible solution, capsule or tablet. Preferably, the administration is by an injectable form.

[0072] As used herein, "treatment", "treat" or "treating" and the like refers to clinical intervention in an attempt to alter the natural course of a disease in the subject being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, antibodies or antibody fragments according to the preset disclosure are used to delay development of a disease or to slow the progression of a disease.

[0073] "Preventing" or "prevention" refers to a reduction in risk of acquiring or developing a disease (i.e., causing at least one of the clinical symptoms of the disease not to develop in a subject that may be exposed to a disease-causing agent, or predisposed to the disease in advance of disease onset). "Prevention" also refers to methods which aim to prevent the onset of a disease or its symptoms or which delay the onset of a disease or its symptoms.

[0074] "Subject" or "species" or as used in this context refers to any mammal, including rodents, such as mouse or rat, and primates, such as cynomolgus monkey (Macaca fascicularis), Marmoset monkey (Callithrix jacchus), rhesus monkey (Macaca mulatta) or humans (Homo sapiens). Preferably, the subject is a primate, most preferably a human.

[0075] The "Fc region" is used to define the C-terminal region of an immunoglobulin heavy chain. The Fc region of an immunoglobulin generally comprises two constant domains, a CH2 domain and a CH3 domain. Although the boundaries of the Fc region of an IgG heavy chain might vary slightly, the human IgG heavy chain Fc region is usually defined to extend from Cys226, or from Pro230, to the C-terminusof the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region mayor may not be present. Unless otherwise specified herein, numbering of amino acid residues in the Fc region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991. Various Fc modifications are commonly used. For a review see for example Antibodies (2020) 9: 64. Silencing functions include (numbering according EU index) the LALA (L234A / L235A), the PA-LALA (L234A / L235A / P329A) and the PG-LALA (L234A / L235A / P329G) mutations, as well as the AEASS mutations (L234A / L235E / G237A / A330S / P331S). A preferred FC modification is PA-LALA. The mutation may also be a mutation which leads to a reduced binding to FcRn, thereby decreasing the in vivo halflife of the antibody. Such mutations include I253A, H310A, H435A and H435Q. Alternatively, the mutation may also a mutation which leads to an increased binding to FcRn, thereby increasing the in vivo half-life of the antibody. Such mutations include T250Q / M428L, M252Y / S254T / T256E (YTE), H433K / N434F and M252Y / S254T / T256E / H433K / N434F.

[0076] The term "effector function" refers to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Non-limiting examples of antibody effector functions include Cl q binding and complement dependent cytotoxicity (CDC); Fc receptor binding and antibodydependent cell-mediated cytotoxicity (ADCC) and / or antibody- dependent cellular phagocytosis (ADCP); down regulation of cell surface receptors (e.g. B cell receptor); and direct cell activation or direct cell inhibition.

[0077] "Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of cytotoxicity in which antibodies bound onto Fc receptors (FcRs) present on certain cytotoxic cells (e.g. NK cells, neutrophils, and macrophages) enable these cytotoxic effector cells to bind specifically to an antigenbearing target cell and subsequently kill the target cell with cytotoxins. The primary cells for mediating ADCC, NK cells, express FcyRIII only, whereas monocytes / macrophages express FcyRI, FcyRII, and FcyRIII.

[0078] "Complement-dependent cytotoxicity" or "CDC" refers to the lysis of a target cell in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (Clq) to antibodies (of the appropriate subclass) of the present disclosure, which are bound to their cognate antigen.

[0079] "Antibody-dependent cellular phagocytosis" or "ADCP" refers to a mechanism of elimination of antibody-coated target cells by internalization by phagocytic cells, such as macrophages or dendritic cells.As used herein, the term "antibody-drug conjugate" or "ADC" refers to an antibody or an antibody fragment that is chemically linked to a second chemical moiety, such as a therapeutic or cytotoxic agent.

[0080] As used herein, the terms "TDCC" and "T cell dependent cytotoxicity" refers to a mechanism of elimination of target cells by cytotoxic T cells. This effect may be induced by the coating of target cells with engineered molecules known as T cell engaging antibodies which enhance the ability of T cells to selectively recognize and kill target cells, such as cancer cells. More precisely, T cell engagers activate T cells by simultaneously binding to receptors e.g. CD3 and tumor associated antigens on tumor cells which elicits the effector function of T cells and result in the lysis of the cross-linked target cells.

[0081] The terms "engineered" or "modified" as used herein includes manipulation of nucleic acids or polypeptides by synthetic means (e.g., by recombinant techniques, in vitro peptide synthesis, by enzymatic or chemical coupling of peptides or some combination of these techniques). Preferably, the antibodies or antibody fragments according to the present disclosure are engineered or modified to improve one or more properties, such as antigen binding, stability, half-life, effector function, immunogenicity, safety and the like.

[0082] "Variant" as used herein refers to a polypeptide that differs from a reference polypeptide by one or more modifications for example amino acid substitutions, insertions or deletions. Variant polypeptides typically retain most of the properties of the reference polypeptide, e.g. binding to the target antigen, but introduce a novel, additional feature or property, e.g. the variant polypeptide has a higher affinity to the target antigen compared to the reference polypeptide or the variant polypeptide is a humanized version of the reference polypeptide.

[0083] The term "amino acid mutation" as used herein is meant to encompass amino acid substitutions, deletions, insertions, and modifications. Any combination of substitution, deletion, insertion, and modification can be made as long as the final construct possesses the desired characteristics, e.g., reduced binding to an Fc receptor. Amino acid sequence deletions and insertions include N-and / or C-terminal deletions and insertions of amino acid residues. Particular amino acid mutations are amino acid substitutions. Amino acid substitutions include replacement by non-naturally occurring amino acids or by naturally occurring amino acid derivatives of the twenty standard amino acids. Amino acid mutations can be generated using genetic or chemical methods well known in the art. Genetic methods may include site-directed mutagenesis, PCR, gene synthesis and the like. It is contemplated that methods of altering the side chain group of an amino acid residue by methods other than genetic engineering, such as chemical modification, may also be useful. Various designations may be usedherein to indicate the same amino acid mutation. For example, a substitution of glycine at position 237 of the antibody Fc region to alanine can be indicated as 237A, G237, G237A, or Gly237Ala.

[0084] The terms "UCHT" refers to an anti-CD3 antibody known in the art and having the amino acid sequence shown in the following Table. This antibody is also referred to as "UCHT-l.v9".

[0085] Table 1:

[0086] Description Amino acid sequence SEQID No.

[0087] EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPG UCHT- VH KGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMN 1 SLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS DIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGK UCHT- VL APKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFA 2 TYYCQQGNTLPWTFGQGTKVEIK UCHT- HCDR1

[0088] GYSFTGY 3 (Chothia)

[0089] UCHT- HCDR2

[0090] NPYKGV 4 (Chothia)

[0091] UCHT - HCDR3

[0092] SGYYGDSDWYFDV 5 (Chothia)

[0093] UCHT- LCDR1

[0094] RASQDIRNYLN 6 (Chothia)

[0095] UCHT- LCDR2

[0096] YTSRLES 7 (Chothia)

[0097] UCHT- LCDR3

[0098] QQGNTLPWT 8 (Chothia)

[0099] UCHT- HCDR1

[0100] GYTMN 9 (Kabat)

[0101] UCHT - HCDR2

[0102] LINPYKGVSTYNQKFKD 10 (Kabat)

[0103] UCHT- HCDR3

[0104] SGYYGDSDWYFDV 5 (Kabat)

[0105] UCHT- LCDR1

[0106] RASQDIRNYLN 6 (Kabat)

[0107]

[0108] UCHT- LCDR2

[0109] YTSRLES 7 (Kabat)

[0110] UCHT- LCDR3

[0111] QQGNTLPWT 8 (Kabat)

[0112]

[0113] Table 2:

[0114] An improved variant of antibody UCHT (UCHT Prime) carries a mutation in the HCDR3 and has the following amino acid sequences.

[0115] Description Amino acid sequence SEQ ID No.

[0116] EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPG UCHT Prime - VH KGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMN 80 SLRAEDTAVYYCARSEYYGDSDWYFDVWGQGTLVTVSS DIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGK UCHT Prime - VL APKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFA 2 TYYCQQGNTLPWTFGQGTKVEIK UCHT Prime - GYSFTGY 3 HCDR1 (Chothia)

[0117] UCHT Prime - NPYKGV 4 HCDR2 (Chothia)

[0118] UCHT Prime - SEYYGDSDWYFDV 81 HCDR3 (Chothia)

[0119] UCHT Prime - LCDR1

[0120] RASQDIRNYLN 6 (Chothia)

[0121] UCHT Prime - LCDR2

[0122] YTSRLES 7 (Chothia)

[0123] UCHT Prime - LCD R3

[0124] QQGNTLPWT 8 (Chothia)

[0125] UCHT Prime - GYTMN 9 HCDR1 (Kabat)

[0126] UCHT Prime - LINPYKGVSTYNQKFKD 10 HCDR2 (Kabat)

[0127] UCHT Prime - SEYYGDSDWYFDV 81 HCDR3 (Kabat)

[0128]

[0129] UCHT Prime - LCDR1

[0130] RASQDIRNYLN 6 (Kabat)

[0131] UCHT Prime - LCDR2

[0132] YTSRLES 7 (Kabat)

[0133] UCHT - Prime LCDR3

[0134] QQGNTLPWT 8 (Kabat)

[0135]

[0136] DETAILED DESCRIPTION OF THE INVENTION

[0137] Molecules and half-molecules of the present disclosure

[0138] The present disclosure relates to molecules which have originally been described as split T cell engaging antibodies which are formed by two of so-called hemibodies (Nat Commun (2019) 26; 10( 1) :5387). Such molecules are composed of two half-molecules (hemibodies). The first of said hemibodies contains a first antigen binding domain and a variable heavy chain (or a variable light chain) of a third antigen binding domain. The second of said hemibodies contains a second antigen binding domain and a variable light chain (or a variable heavy chain) of a third antigen binding domain. Said variable heavy chain of the third antigen binding domain and said variable light chain of the third antigen binding domain are capable to associate with each other to form a full molecule, also referred to as BiTACs. Half-molecules, i.e. hemibodies, are also referred to as BiTAC precursors or BiTAC precursor molecules.

[0139] Formation of BiTACs is often hampered by association of the variable light chain of the first binding domain to the variable heavy chain of the third antigen binding domain, rather than the first antigen binding domain. The present invention identified approaches to avoid such mispairing.

[0140] In the broadest sense, the present disclosure provides a molecule comprising

[0141] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, andb) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0142] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein the variable light chain of the first binding domain does not associate with the variable heavy chain of the third antigen binding domain.

[0143] Accordingly, the present disclosure provides a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0144] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein

[0145] i) said variable heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 with a amino acid substitution at position L45 (according Chothia), ii) the variable light chain of said first antigen binding domain has a mutation at position 86 (according to Chothia), or

[0146] ill) in said first antigen binding domain at least the VH domain and VL domain are replaced by each other.

[0147] In certain embodiments, said variable heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 with a amino acid substitution at position L45 (according Chothia) to alanine (A).

[0148] In certain embodiments, said variable heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 with a amino acid substitution at position L45 (according Chothia) to arginine (R).

[0149] In certain embodiments, said variable heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 80 with a amino acid substitution at position L45 (according Chothia) to alanine (A) or arginine (R).ln certain embodiments, said variable light chain of said first antigen binding domain has a mutation at position 86 (according to Chothia), wherein said mutation to is selected from a mutation to alanine (A), proline (P), serine (S), tryptophan (W), arginine (R), glutamic acid (E), phenylalanine (F), methionine (M), glutamine (Q) or leucine (L) at position 86 (according to Chothia).In certain embodiments, said variable light chain of said first antigen binding domain has a mutation at position 86 (according to Chothia) to alanine (A).

[0150] Mutations in the variable heavy chain of the third antigen binding domain

[0151] In certain embodiments, the present disclosure relates to a molecule comprising

[0152] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0153] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0154] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein said third antigen binding domain comprises a variable heavy chain with a mutation which prevents pairing of the light chain of the first binding domain to the variable heavy chain of the third antigen binding domain.

[0155] In certain embodiments, the present disclosure relates to a molecule comprising

[0156] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0157] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0158] wherein said third antigen binding domain is a variant of antibody UCHT, wherein said variant of antibody UCHT comprises a variable heavy chain with a mutation which avoids pairing of the light chain of the first binding domain to the variable heavy chain of antibody UCHT.

[0159] In certain embodiments, the present disclosure relates to a molecule comprising

[0160] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0161] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0162] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein said third antigen binding domain comprises a variable heavy chain of SEQ. ID No. 1 or 80

[0163] 11with an amino acid substitution at position L45 (according Chothia) and a variable light chain of SEQ ID No. 2.

[0164] In certain embodiments, the present disclosure relates to a molecule comprising

[0165] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0166] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0167] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 76 or 77 and a variable light chain of SEQ ID No. 2.

[0168] In certain embodiments, the present disclosure relates to a molecule comprising

[0169] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0170] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0171] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 76 and a variable light chain of SEQ ID No. 2.

[0172] In certain embodiments, the present disclosure relates to a molecule comprising

[0173] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0174] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0175] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 77 and a variable light chain of SEQ ID No. 2.

[0176] In certain embodiments, the present disclosure relates to a molecule comprising

[0177] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, andb) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0178] wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 76 or 77 and a variable light chain of SEQ ID No. 2.

[0179] In certain embodiments, the present disclosure relates to a molecule comprising

[0180] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0181] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0182] wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 76 and a variable light chain of SEQ ID No. 2.

[0183] In certain embodiments, the present disclosure relates to a molecule comprising

[0184] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0185] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0186] wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 77 and a variable light chain of SEQ ID No. 2.

[0187] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0188] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0189] wherein said variable heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 with an amino acid substitution at position L45 (according Chothia).

[0190] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0191] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), andwherein said third antigen binding domain is a variant of antibody UCHT, wherein said variant of antibody UCHT comprises a variable heavy chain with a mutation which avoids pairing of the light chain of the first binding domain to the variable heavy chain of antibody UCHT.

[0192] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0193] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0194] wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 with an amino acid substitution at position L45 (according Chothia).

[0195] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0196] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0197] wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 76 or 77.

[0198] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0199] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0200] wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 76.

[0201] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0202] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0203] wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 77.Mutations in the variable light chain of the first antigen binding domain

[0204] In certain embodiments, the present disclosure relates to a molecule comprising

[0205] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0206] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0207] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein the variable light chain of said first antigen binding domain has a mutation at position Y86 (according to Chothia).

[0208] In certain embodiments, the present disclosure relates to a molecule comprising

[0209] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0210] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0211] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein the variable light chain of said first antigen binding domain has a mutation to lysine, valine, threonine, asparagine, aspartic acid, cysteine, histidine, glycine, alanine, proline, serine, tryptophan, arginine, glutamic acid, phenylalanine, methionine, glutamine or leucine at position Y86 (according to Chothia).

[0212] In certain embodiments, the present disclosure relates to a molecule comprising

[0213] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0214] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0215] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein the variable light chain of said first antigen binding domain has a mutation at position Y86 (according to Chothia).

[0216] In certain embodiments, the present disclosure relates to a molecule comprisinga) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0217] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0218] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein the variable light chain of said first antigen binding domain has a mutation to alanine, proline, serine, tryptophan, arginine, glutamic acid, phenylalanine, methionine, glutamine or leucine at position Y86 (according to Chothia).

[0219] In certain embodiments, the present disclosure relates to a molecule comprising

[0220] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0221] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0222] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein the variable light chain of said first antigen binding domain has a mutation to methionine, leucine, alanine, serine, proline, glutamine, arginine or glutamic acid at position Y86 (according to Chothia).

[0223] In certain embodiments, the present disclosure relates to a molecule comprising

[0224] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0225] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0226] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein the variable light chain of said first antigen binding domain has a mutation to alanine, serine, proline, glutamine, arginine or glutamic acid at position Y86 (according to Chothia).

[0227] In certain embodiments, the present disclosure relates to a molecule comprising

[0228] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0229] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), wherein the variable light chain of said first antigen binding domain has a mutation to alanine, proline, serine, tryptophan, arginine, glutamic acid, phenylalanine, methionine, glutamine or leucine at position 86 (according to Chothia), and

[0230] wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is a mutation to alanine. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is a mutation to proline. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is a mutation to serine. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is a mutation to tryptophan. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is a mutation to arginine. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is a mutation to glutamic acid. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is a mutation to phenylalanine. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is a mutation to methionine. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is a mutation to glutamine. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is a mutation to leucine. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is a mutation to lysine. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is a mutation to valine. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is a mutation to threonine. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is a mutation to asparagine. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is a mutation to aspartic acid. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is a mutation to cysteine. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigenbinding domain is a mutation to histidine. In certain embodiments, said mutation at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is a mutation to glycine.

[0231] In certain embodiments, the present disclosure relates to a molecule comprising

[0232] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0233] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0234] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein the variable light chain of said first antigen binding domain has a mutation to alanine at position 86 (according to Chothia).

[0235] In certain embodiments, the present disclosure relates to a molecule comprising

[0236] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0237] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0238] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), wherein the variable light chain of said first antigen binding domain has a mutation to alanine at position 86 (according to Chothia), and

[0239] wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2.

[0240] In certain embodiments, the present disclosure relates to a molecule comprising

[0241] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0242] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0243] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein the variable light chain of said first antigen binding domain has a mutation to serine at position 86 (according to Chothia).In certain embodiments, the present disclosure relates to a molecule comprising

[0244] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0245] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0246] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), wherein the variable light chain of said first antigen binding domain has a mutation to serine at position 86 (according to Chothia), and

[0247] wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2.

[0248] In certain embodiments, the present disclosure relates to a molecule comprising

[0249] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0250] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0251] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein the variable light chain of said first antigen binding domain has a mutation to proline at position 86 (according to Chothia).

[0252] In certain embodiments, the present disclosure relates to a molecule comprising

[0253] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0254] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0255] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), wherein the variable light chain of said first antigen binding domain has a mutation to proline at position 86 (according to Chothia), and

[0256] wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2.

[0257] In certain embodiments, the present disclosure relates to a molecule comprisinga) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0258] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0259] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein the variable light chain of said first antigen binding domain has a mutation to glutamine at position 86 (according to Chothia).

[0260] In certain embodiments, the present disclosure relates to a molecule comprising

[0261] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0262] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0263] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), wherein the variable light chain of said first antigen binding domain has a mutation to glutamine at position 86 (according to Chothia), and

[0264] wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2.

[0265] In certain embodiments, the present disclosure relates to a molecule comprising

[0266] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0267] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0268] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein the variable light chain of said first antigen binding domain has a mutation to arginine at position 86 (according to Chothia).

[0269] In certain embodiments, the present disclosure relates to a molecule comprising

[0270] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, andb) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0271] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), wherein the variable light chain of said first antigen binding domain has a mutation to arginine at position 86 (according to Chothia), and

[0272] wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2.

[0273] In certain embodiments, the present disclosure relates to a molecule comprising

[0274] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0275] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0276] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein the variable light chain of said first antigen binding domain has a mutation to glutamic acid at position 86 (according to Chothia).

[0277] In certain embodiments, the present disclosure relates to a molecule comprising

[0278] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0279] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0280] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), wherein the variable light chain of said first antigen binding domain has a mutation to glutamic acid at position 86 (according to Chothia), and

[0281] wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2.

[0282] Tyrosine 86 is located in the framework 3 of the variable light chain. It is universally conserved in the variable light chain sequences of antibodies of all sub-types, i.e. kappal, kappa2, kappa 3, kappa 4, lambda 1, lambda 2 and lambda 3. See for example Proteins (2009) 76: 99-114 and MolecularImmunology (2016) 70: 63-71. In line herewith, the effect associated with a mutations of this residues was observed for all antibodies tested, and irrespective of antigen specificity and amino acid context.

[0283] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0284] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0285] wherein the variable light chain of said first antigen binding domain has a mutation to alanine at position 86 (according to Chothia).

[0286] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0287] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3),

[0288] wherein the variable light chain of said first antigen binding domain has a mutation to alanine at position 86 (according to Chothia) and

[0289] wherein said heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80.

[0290] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0291] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0292] wherein the variable light chain of said first antigen binding domain has a mutation to serine at position 86 (according to Chothia).

[0293] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0294] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3),wherein the variable light chain of said first antigen binding domain has a mutation to serine at position 86 (according to Chothia) and

[0295] wherein said heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80.

[0296] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0297] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0298] wherein the variable light chain of said first antigen binding domain has a mutation to proline at position 86 (according to Chothia).

[0299] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0300] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3),

[0301] wherein the variable light chain of said first antigen binding domain has a mutation to proline at position 86 (according to Chothia) and

[0302] wherein said heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80.

[0303] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0304] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0305] wherein the variable light chain of said first antigen binding domain has a mutation to glutamine at position 86 (according to Chothia).

[0306] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3),

[0307] wherein the variable light chain of said first antigen binding domain has a mutation to glutamine at position 86 (according to Chothia) and

[0308] wherein said heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80.

[0309] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0310] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0311] wherein the variable light chain of said first antigen binding domain has a mutation to arginine at position 86 (according to Chothia).

[0312] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0313] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3),

[0314] wherein the variable light chain of said first antigen binding domain has a mutation to arginine at position 86 (according to Chothia) and

[0315] wherein said heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80.

[0316] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0317] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0318] wherein the variable light chain of said first antigen binding domain has a mutation to glutamic acid at position 86 (according to Chothia).

[0319] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3),

[0320] wherein the variable light chain of said first antigen binding domain has a mutation to glutamic acid at position 86 (according to Chothia) and

[0321] wherein said heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80.

[0322] CrossMab format of the first antigen binding domain

[0323] In certain embodiments, the present disclosure relates to a molecule comprising

[0324] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0325] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0326] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein said first antigen binding domain is in CrossMab format.

[0327] In certain embodiments, the present disclosure relates to a molecule comprising

[0328] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0329] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0330] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein in said first antigen binding domain the variable light chain is replaced by the variable heavy chain of said first antigen binding domain and the constant light chain domain CL is replaced by the constant heavy chain domain CHI of said first antigen binding domain, and the variable heavy chain is replaced by the variable light chain first of said antigen binding domain and the constant heavy chain domain CHI is replaced by the constant light chain domain CL of said first antigen binding domain.

[0331] In certain embodiments, the present disclosure relates to a molecule comprisinga) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0332] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0333] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein in said first antigen binding domain the variable light chain is replaced by the variable heavy chain of said first antigen binding domain, and the variable heavy chain is replaced by the variable light chain first of said antigen binding domain.

[0334] In certain embodiments, the present disclosure relates to a molecule comprising

[0335] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0336] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0337] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein in said first antigen binding domain the variable light chain is replaced by the variable heavy chain of said first antigen binding domain and the constant light chain domain CL is replaced by the constant heavy chain domain CHI of said first antigen binding domain, and the variable heavy chain is replaced by the variable light chain first of said antigen binding domain and the constant heavy chain domain CHI is replaced by the constant light chain domain CL of said first antigen binding domain, and

[0338] wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2.

[0339] In certain embodiments, the present disclosure relates to a molecule comprising

[0340] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0341] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0342] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), andwherein in said first antigen binding domain the variable light chain is replaced by the variable heavy chain of said first antigen binding domain, and the variable heavy chain is replaced by the variable light chain first of said antigen binding domain, and

[0343] wherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2.

[0344] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0345] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0346] wherein said first antigen binding domain is in CrossMab format.

[0347] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0348] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0349] in said first antigen binding domain at least the VH domain and VL domain are replaced by each other.

[0350] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0351] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0352] wherein in said first antigen binding domain the variable light chain is replaced by the variable heavy chain of said first antigen binding domain and the constant light chain domain CL is replaced by the constant heavy chain domain CHI of said first antigen binding domain, and the variable heavy chain is replaced by the variable light chain first of said antigen binding domain and the constant heavy chain domain CHI is replaced by the constant light chain domain CL of said first antigen binding domain.

[0353] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3),

[0354] wherein in said first antigen binding domain the variable light chain is replaced by the variable heavy chain of said first antigen binding domain and the constant light chain domain CL is replaced by the constant heavy chain domain CHI of said first antigen binding domain, and the variable heavy chain is replaced by the variable light chain first of said antigen binding domain and the constant heavy chain domain CHI is replaced by the constant light chain domain CL of said first antigen binding domain, and

[0355] wherein said heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1.

[0356] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0357] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0358] wherein in said first antigen binding domain the variable light chain is replaced by the variable heavy chain of said first antigen binding domain, and the variable heavy chain is replaced by the variable light chain first of said antigen binding domain.

[0359] In certain embodiments, the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0360] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3),

[0361] wherein in said first antigen binding domain the variable light chain is replaced by the variable heavy chain of said first antigen binding domain, and the variable heavy chain is replaced by the variable light chain first of said antigen binding domain, and

[0362] wherein said heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80.First and second antigen binding domain

[0363] Principally any antigen binding domain can be used as the first antigen binding domain and the second antigen binding domain. Preferably, the first antigen binding domain and the second antigen binding domain bind to different tumor associated antigens.

[0364] Various binding domains were exemplary used in the present invention.

[0365] The antigen-binding domain specific for HER2 comprises the following amino acid sequence.

[0366] Table 3:

[0367] Description Amino acid sequence SEQ ID No.

[0368] EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLE HER2 - VH WVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAV 14 YYCSRWGGDGFYAMDYWGQGTLVTVSS DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKL HER2 - VL LI YSAS F LYSG VPS R FSGS RSGTD FTLTISS LQP E D FATYYCQQH YTTP P 15 TFGQGTKVEIK HER2 - HCDR1

[0369] GFNIKDT 16 (Chothia)

[0370] HER2 - HCDR2

[0371] YPTNGY 17 (Chothia)

[0372] HER2 - HCDR3

[0373] WGGDGFYAMDY 18 (Chothia)

[0374] HER2 - LCDR1

[0375] RASQDVNTAVA 19 (Chothia)

[0376] HER2 - LCDR2

[0377] SASFLYS 20 (Chothia)

[0378] HER2 - LCDR3

[0379] QQHYTTPPT 21 (Chothia)

[0380] HER2 - HCDR1

[0381] DTYIH 22 (Kabat)

[0382] HER2 - HCDR2

[0383] RIYPTNGYTRYADSVKG 23 (Kabat)

[0384]

[0385] HER2 - HCDR3

[0386] WGGDGFYAMDY 18 (Kabat)

[0387] HER2 - LCDR1

[0388] RASQDVNTAVA 19 (Kabat)

[0389] HER2 - LCDR2

[0390] SASFLYS 20 (Kabat)

[0391] HER2 - LCDR3

[0392] QQHYTTPPT 21 (Kabat)

[0393]

[0394] The antigen-binding domain specific for SLAMF7 comprises the following amino acid sequence.

[0395] Table 4:

[0396] Description Amino acid sequence SEQ ID No.

[0397] EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGL SLAM F7 - VH EWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVY 24 YCARPDGNYWYFDVWGQGTLVTVSS DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLL SLAMF7 - VL IYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYP 25 YTFGQGTKVEIK SLAMF7 - HCDR1

[0398] GFDFSRY 26 (Chothia)

[0399] SLAMF7 - HCDR2

[0400] NPDSST 27 (Chothia)

[0401] SLAMF7 - HCDR3

[0402] PDGNYWYFDV 28 (Chothia)

[0403] SLAMF7 - LCDR1

[0404] KASQDVGIAVA 29 (Chothia)

[0405] SLAMF7 - LCDR2

[0406] WASTRHT 30 (Chothia)

[0407] SLAMF7 - LCDR3

[0408] QQYSSYPYT 31 (Chothia)

[0409] SLAMF7 - HCDR1

[0410] RYWMS 32 (Kabat)

[0411]

[0412] SLAMF7 - HCDR2

[0413] EINPDSSTINYAPSLKD 33 (Kabat)

[0414] SLAMF7 - HCDR3

[0415] PDGNYWYFDV 28 (Kabat)

[0416] SLAMF7 - LCDR1

[0417] KASQDVGIAVA 29 (Kabat)

[0418] SLAMF7 - LCDR2

[0419] WASTRHT 30 (Kabat)

[0420] SLAMF7 - LCDR3

[0421] QQYSSYPYT 31 (Kabat)

[0422]

[0423] The antigen-binding domain specific for CD38 comprises the following amino acid sequence.

[0424] Table 5:

[0425] Description Amino acid sequence SEQ ID No.

[0426] QVQLVESGGG LVQPGGSLRLSCAASG FTFSSYG M H WVRQAPG KGL CD38 - VH EWVSNIYSDGSNTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTA 34 VYYCARNMYRWPFHYFFDYWGQGTLVTVSS DIELTQPPSVSVAPGQ.TARISCSGDNIGNKYVSWYQQKPGQAPVVVI

[0427] CD38 - VL YGDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSSYDSSYF 35 VFGGGTKLTVL CD38 - HCDR1

[0428] GFTFSSY 36 (Chothia)

[0429] CD38 - HCDR2

[0430] YSDGSN 37 (Chothia)

[0431] CD38 - HCDR3

[0432] NMYRWPFHYFFDY 38 (Chothia)

[0433] CD38 - LCDR1

[0434] SGDNIGNKYVS 39 (Chothia)

[0435] CD38 - LCDR2

[0436] GDNNRPS 40 (Chothia)

[0437] CD38 - LCDR3

[0438] SSYDSSYFV 41 (Chothia)

[0439]

[0440] CD38 - HCDR1

[0441] SYGMH 42 (Kabat)

[0442] CD38 - HCDR2

[0443] NIYSDGSNTFYADSVKG 43 (Kabat)

[0444] CD38 - HCDR3

[0445] NMYRWPFHYFFDY 38 (Kabat)

[0446] CD38 - LCDR1

[0447] SGDNIGNKYVS 39 (Kabat)

[0448] CD38 - LCDR2

[0449] GDNNRPS 40 (Kabat)

[0450] CD38 - LCDR3

[0451] SSYDSSYFV 41 (Kabat)

[0452]

[0453] The antigen-binding domain specific for EpCAM comprises the following amino acid sequence.

[0454] Table 6:

[0455] Description Amino acid sequence SEQ ID No.

[0456] EVQLLEQSGAELVRPGTSVKISCKASGYAFTNYWLGWVKQRPGHGL

[0457] EpCAM - VH EWIGDIFPGSGNIHYNEKFKGKATLTADKSSSTAYMQLSSLTFEDSAV 44 YFCARLRNWDEPM DYWGQGTTVTVSS ELVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKP

[0458] EpCAM - VL GQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYC 45 QNDYSYPLTFGAGTKLEIK

[0459] EpCAM - HCDR1

[0460] GYAFTNY 46 (Chothia)

[0461] EpCAM - HCDR2

[0462] FPGSGN 47 (Chothia)

[0463] EpCAM - HCDR3

[0464] LRNWDEPMDY 48 (Chothia)

[0465] EpCAM - LCDR1

[0466] KSSQSLLNSGNQKNYLT 49 (Chothia)

[0467] EpCAM - LCDR2

[0468] WASTRES 50 (Chothia)

[0469]

[0470] EpCAM - LCDR3

[0471] QNDYSYPLT 51 (Chothia)

[0472] EpCAM - HCDR1

[0473] NYWLG 52 (Kabat)

[0474] EpCAM - HCDR2

[0475] DIFPGSGNIHYNEKFKG 53 (Kabat)

[0476] EpCAM - HCDR3

[0477] LRNWDEPMDY 48 (Kabat)

[0478] EpCAM - LCDR1

[0479] KSSQSLLNSGNQKNYLT 49 (Kabat)

[0480] EpCAM - LCDR2

[0481] WASTRES 50 (Kabat)

[0482] EpCAM - LCDR3

[0483] QNDYSYPLT 51 (Kabat)

[0484]

[0485] In certain embodiments of the present disclosure, the first antigen binding domain and the second antigen binding domain are specific for tumor associated antigens selected from HER2, EpCAM, CD19, MSLN, DLL3, FLT3, EGFR, CD33, CD38, MUC17, CLDN18.2, CDH3, CD70, BCMA,PSMA, CEACAM5, HER3, STEAP-1, TROP-2, NECTIN-4, B7-H3, B7-H4, MUC16, FOLR1, CD200, CLDN6, GPRC5D, EGFRviii, MUC1 and 5T4.

[0486] In certain embodiments of the present disclosure, the first antigen binding domain and the second antigen binding domain are specific for tumor associated antigens selected from HER2, SLAMF7, EpCAM and CD38.

[0487] In certain embodiments of the present disclosure, the first antigen binding domain is specific for HER2 and the second antigen binding domain is specific for EpCAM.

[0488] In certain embodiments of the present disclosure, the first antigen binding domain is specific for CD38 and the second antigen binding domain is specific for SLAMF7.

[0489] In certain embodiments of the present disclosure relates to a molecule comprising

[0490] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, andb) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0491] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), wherein i) said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 with an amino acid substitution at position L45 (according Chothia) and a variable light chain of SEQ ID No.2,

[0492] ii) the variable light chain of said first antigen binding domain has a mutation at position 86 (according to Chothia), preferably wherein said mutation is a mutation to alanine, or ill) in said first antigen binding domain at least the VH domain and VL domain are replaced by each other, and

[0493] wherein said first antigen binding domain and said second antigen binding domain are specific for tumor associated antigens selected from HER2, EpCAM, CD19, MSLN, DLL3, FLT3, EGFR, CD33, CD38, MUC17, CLDN18.2, CDH3, CD70, BCMA,PSMA, CEACAM5, HER3, STEAP-1, TROP-2, NECTIN-4, B7-H3, B7-H4, MUC16, F0LR1, CD200, CLDN6, GPRC5D, EGFRviii, MUC1 and 5T4.

[0494] In certain embodiments of the present disclosure relates to a molecule comprising

[0495] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0496] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0497] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), wherein i) said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 with an amino acid substitution at position L45 (according Chothia) and a variable light chain of SEQ ID No.2,

[0498] ii) the variable light chain of said first antigen binding domain has a mutation at position 86 (according to Chothia), preferably wherein said mutation is a mutation to alanine, or ill) in said first antigen binding domain at least the VH domain and VL domain are replaced by each other, and

[0499] wherein said first antigen binding domain and said second antigen binding domain are specific for tumor associated antigens selected from HER2, SLAMF7, EpCAM and CD38. In certain preferredembodiments, the first antigen binding domain is specific for HER2 and the second antigen binding domain is specific for EpCAM. In other preferred embodiments, the first antigen binding domain is specific for CD38 and the second antigen binding domain is specific for SLAMF7.

[0500] In certain embodiments of the present disclosure relates to a molecule comprising

[0501] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0502] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0503] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), wherein i) said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 with an amino acid substitution at position L45 (according Chothia) and a variable light chain of SEQ ID No.2,

[0504] ii) the variable light chain of said first antigen binding domain has a mutation at position 86 (according to Chothia), preferably wherein said mutation is a mutation to alanine, or ill) in said first antigen binding domain at least the VH domain and VL domain are replaced by each other, and

[0505] wherein said first antigen binding domain or said second antigen binding domain comprises a variable heavy chain comprising a HCDR1 of SEQ ID No. 16, a HCDR2 of SEQ ID No. 17 and a HCDR3 of SEQ ID No. 18, and a variable light chain comprising a LCDR1 of SEQ ID No. 19, a LCDR2 of SEQ ID No. 20 and a LCDR3 of SEQ ID No. 21.

[0506] In certain embodiments of the present disclosure relates to a molecule comprising

[0507] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0508] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0509] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), wherein i) said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 with an amino acid substitution at position L45 (according Chothia) and a variable light chain of SEQ ID No.2,ii) the variable light chain of said first antigen binding domain has a mutation to alanine at position 86 (according to Chothia), or

[0510] ill) in said first antigen binding domain at least the VH domain and VL domain are replaced by each other, and

[0511] wherein said first antigen binding domain or said second antigen binding domain comprises a variable heavy chain comprising a HCDR1 of SEQ ID No. 26, a HCDR2 of SEQ ID No. 27 and a HCDR3 of SEQ ID No. 28, and a variable light chain comprising a LCDR1 of SEQ ID No. 29, a LCDR2 of SEQ ID No. 30 and a LCDR3 of SEQ ID No. 31.

[0512] In certain embodiments of the present disclosure relates to a molecule comprising

[0513] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0514] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0515] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), wherein i) said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 with an amino acid substitution at position L45 (according Chothia) and a variable light chain of SEQ ID No.2,

[0516] ii) the variable light chain of said first antigen binding domain has a mutation at position 86 (according to Chothia), preferably wherein said mutation is a mutation to alanine, or ill) in said first antigen binding domain at least the VH domain and VL domain are replaced by each other, and

[0517] wherein said first antigen binding domain or said second antigen binding domain comprises a variable heavy chain comprising a HCDR1 of SEQ ID No. 36, a HCDR2 of SEQ ID No. 37 and a HCDR3 of SEQ ID No. 38, and a variable light chain comprising a LCDR1 of SEQ ID No. 39, a LCDR2 of SEQ ID No. 41 and a LCDR3 of SEQ ID No. 41.

[0518] In certain embodiments of the present disclosure relates to a molecule comprising

[0519] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, andb) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0520] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), wherein i) said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 with an amino acid substitution at position L45 (according Chothia) and a variable light chain of SEQ ID No.2,

[0521] ii) the variable light chain of said first antigen binding domain has a mutation at position 86 (according to Chothia), preferably wherein said mutation is a mutation to alanine, or ill) in said first antigen binding domain at least the VH domain and VL domain are replaced by each other, and

[0522] wherein said first antigen binding domain or said second antigen binding domain comprises a variable heavy chain comprising a HCDR1 of SEQ ID No. 46, a HCDR2 of SEQ ID No. 47 and a HCDR3 of SEQ ID No. 48, and a variable light chain comprising a LCDR1 of SEQ ID No. 49, a LCDR2 of SEQ ID No. 50 and a LCDR3 of SEQ ID No. 51.

[0523] In certain embodiments of the present disclosure relates to a molecule comprising

[0524] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0525] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0526] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), wherein i) said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 with an amino acid substitution at position L45 (according Chothia) and a variable light chain of SEQ ID No.2,

[0527] ii) the variable light chain of said first antigen binding domain has a mutation at position 86 (according to Chothia), preferably wherein said mutation is a mutation to alanine, or ill) in said first antigen binding domain at least the VH domain and VL domain are replaced by each other,wherein said first antigen binding domain comprises a variable heavy chain comprising a HCDR1 of SEQ ID No. 16, a HCDR2 of SEQ ID No. 17 and a HCDR3 of SEQ ID No. 18, and a variable light chain comprising a LCDR1 of SEQ ID No. 19, a LCDR2 of SEQ ID No. 20 and a LCDR3 of SEQ ID No. 21, and wherein said second antigen binding domain comprises a variable heavy chain comprising a HCDR1 of SEQ ID No. 46, a HCDR2 of SEQ ID No. 47 and a HCDR3 of SEQ ID No. 48, and a variable light chain comprising a LCDR1 of SEQ ID No. 49, a LCDR2 of SEQ ID No. 50 and a LCDR3 of SEQ ID No. 51.

[0528] In certain embodiments of the present disclosure relates to a molecule comprising

[0529] a) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0530] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0531] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), wherein i) said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 with an amino acid substitution at position L45 (according Chothia) and a variable light chain of SEQ ID No.2,

[0532] ii) the variable light chain of said first antigen binding domain has a mutation at position 86 (according to Chothia), preferably wherein said mutation is a mutation to alanine, or ill) in said first antigen binding domain at least the VH domain and VL domain are replaced by each other,

[0533] wherein said first antigen binding domain comprises a variable heavy chain comprising a HCDR1 of SEQ ID No. 36, a HCDR2 of SEQ ID No. 37 and a HCDR3 of SEQ ID No. 38, and a variable light chain comprising a LCDR1 of SEQ ID No. 39, a LCDR2 of SEQ ID No. 41 and a LCDR3 of SEQ ID No. 41, and wherein said second antigen binding domain comprises a variable heavy chain comprising a HCDR1 of SEQ ID No. 26, a HCDR2 of SEQ ID No. 27 and a HCDR3 of SEQ ID No. 28, and a variable light chain comprising a LCDR1 of SEQ ID No. 29, a LCDR2 of SEQ ID No. 30 and a LCDR3 of SEQ ID No. 31.

[0534] In certain embodiments of the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0535] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and whereini) said variable heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 with a amino acid substitution at position L45 (according Chothia), ii) the variable light chain of said first antigen binding domain has a mutation to alanine at position 86 (according to Chothia), or

[0536] ill) in said first antigen binding domain at least the VH domain and VL domain are replaced by each other, and

[0537] wherein said first antigen binding domain comprises a variable heavy chain comprising a HCDR1 of SEQ. ID No. 16, a HCDR2 of SEQ ID No. 17 and a HCDR3 of SEQ ID No. 18, and a variable light chain comprising a LCDR1 of SEQ ID No. 19, a LCDR2 of SEQ ID No. 20 and a LCDR3 of SEQ ID No. 21.

[0538] In certain embodiments of the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0539] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein

[0540] i) said variable heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 with an amino acid substitution at position L45 (according Chothia), ii) the variable light chain of said first antigen binding domain has a mutation at position 86 (according to Chothia), preferably wherein said mutation is a mutation to alanine, or

[0541] ill) in said first antigen binding domain at least the VH domain and VL domain are replaced by each other, and

[0542] wherein said first antigen binding domain comprises a variable heavy chain comprising a HCDR1 of SEQ ID No. 26, a HCDR2 of SEQ ID No. 27 and a HCDR3 of SEQ ID No. 28, and a variable light chain comprising a LCDR1 of SEQ ID No. 29, a LCDR2 of SEQ ID No. 30 and a LCDR3 of SEQ ID No. 31.

[0543] In certain embodiments of the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0544] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein

[0545] i) said variable heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 with an amino acid substitution at position L45 (according Chothia),ii) the variable light chain of said first antigen binding domain has a mutation at position 86 (according to Chothia), preferably wherein said mutation is a mutation to alanine, or

[0546] ill) in said first antigen binding domain at least the VH domain and VL domain are replaced by each other, and

[0547] wherein said first antigen binding domain comprises a variable heavy chain comprising a HCDR1 of SEQ ID No. 36, a HCDR2 of SEQ ID No. 37 and a HCDR3 of SEQ ID No. 38, and a variable light chain comprising a LCDR1 of SEQ ID No. 39, a LCDR2 of SEQ ID No. 41 and a LCDR3 of SEQ ID No. 41.

[0548] In certain embodiments of the present disclosure relates to a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0549] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein

[0550] i) said variable heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 with an amino acid substitution at position L45 (according Chothia), ii) the variable light chain of said first antigen binding domain has a mutation at position 86 (according to Chothia), preferably wherein said mutation is a mutation to alanine, or

[0551] ill) in said first antigen binding domain at least the VH domain and VL domain are replaced by each other, and

[0552] wherein said first antigen binding domain comprises a variable heavy chain comprising a HCDR1 of SEQ ID No. 46, a HCDR2 of SEQ ID No. 47 and a HCDR3 of SEQ ID No. 48, and a variable light chain comprising a LCDR1 of SEQ ID No. 49, a LCDR2 of SEQ ID No. 50 and a LCDR3 of SEQ ID No. 51.

[0553] The full-length sequences of the heavy chains of the BiTAC precursor molecules generated and utilized in the present invention are as follows.

[0554] Table 7:

[0555] QVQLVESGGG LVQPGGSLRLSCAASG FTFSSYG M H WVRQAPG KGL EWVSNIYSDGSNTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTA VYYCARNMYRWPFHYFFDYWGQGTLVTVSSASTKGPSVFPLAPSSK VBP-100 - HC1 60

[0556] STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP CPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF

[0557]

[0558] NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSGGGG SGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQ APGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSL RAEDTAVYYCARSEYYGDSDWYFDVWGQGTLVTVSS QVQLVESGGG LVQPGGSLRLSCAASG FTFSSYG M H WVRQAPG KGL EWVSNIYSDGSNTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTA VYYCARNMYRWPFHYFFDYWGQGTLVTVSSASTKGPSVFPLAPSSK STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP CPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF VBP-101- HC1 NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK 60

[0559] CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSGGGG SGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQ APGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSL RAEDTAVYYCARSEYYGDSDWYFDVWGQGTLVTVSS QVQLVESGGG LVQPGGSLRLSCAASG FTFSSYG M H WVRQAPG KGL EWVSNIYSDGSNTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTA VYYCARNMYRWPFHYFFDYWGQGTLVTVSSASTKGPSVFPLAPSSK STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP CPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF VBP-102- HC1 NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK 62

[0560] CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSGGGG SGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQ APGKGAEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSL RAEDTAVYYCARSEYYGDSDWYFDVWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLE VBP-200- HC1 63

[0561] WVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAV

[0562]

[0563] YYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQ.TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA PEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSGGGGSG GGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAP GKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRA EDTAVYYCARSEYYGDSDWYFDVWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLE WVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAV YYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQ.TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA PEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VBP-201- HC1 VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS 63

[0564] NKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSGGGGSG GGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAP GKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRA EDTAVYYCARSEYYGDSDWYFDVWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLE WVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAV YYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQ.TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA VBP-202- HC1 PEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY 65

[0565] VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSGGGGSG GGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAP

[0566]

[0567] GKGREWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRA EDTAVYYCARSEYYGDSDWYFDVWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGL EWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVY YCARPDGNYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGG TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQ.TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEA AGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD VBP-300- HC1 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK 66

[0568] ALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAP KLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTL PWTFGQGTKVEIK EVQLLEQSGAELVRPGTSVKISCKASGYAFTNYWLGWVKQRPGHGL EWIGDIFPGSGNIHYNEKFKGKATLTADKSSSTAYMQLSSLTFEDSAV YFCARLRNWDEPMDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSSLGTQ.TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD VBP-400-HC1 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK 67

[0569] ALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGSGGGGSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAP KLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTL PWTFGQGTKVEIK DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKL LI YSAS F LYSG VPS R FSGS RSGTD FTLTISS LQP E D FATYYCQQH YTTP P TFGQGTKVEIKSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP VBP-500-HC1 VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ.TYICN 68

[0570] VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG

[0571]

[0572] QPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPGGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLV QPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGV STYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSEYYGD SDWYFDVWGQGTLVTVSS

[0573]

[0574] The full-length sequences of the light chains of the BiTAC precursor molecules generated and utilized in the present invention are as follows.

[0575] Table 8:

[0576] DIELTQPPSVSVAPGQ.TARISCSGDNIGNKYVSWYQQKPGQAPVVVI CD38 light chain YGDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSSYDSSYF

[0577] (used in VBP-100 VFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGA 69 and VBP-102) VTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHR SYSCQVTH EGSTVEKTVAPTECS DIELTQPPSVSVAPGQ.TARISCSGDNIGNKYVSWYQQKPGQAPVVVI YGDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADAYCSSYDSSYF CD38 light chain

[0578] VFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGA 70 (used in VBP-101)

[0579] VTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHR SYSCQVTH EGSTVEKTVAPTECS DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKL HER2 light chain LI YSAS F LYSG VPS R FSGS RSGTD FTLTISS LQP E D FATYYCQQH YTTP P

[0580] (used in VBP-200 TFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK 71 and VBP-202) VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY ACEVTHQGLSSPVTKSFNRGEC DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKL LIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATAYCQQHYTTPP HER2 light chain 1

[0581] TFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK 72 (used in VBP-201)

[0582] VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY ACEVTHQGLSSPVTKSFNRGEC DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLL SLAMF7 light chain

[0583] IYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYP 73 (used in VBP-300)

[0584] YTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREA

[0585]

[0586] KVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKV YACEVTHQGLSSPVTKSFNRGEC ELVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKP GQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYC

[0587] EpCAM light chain

[0588] QNDYSYPLTFGAGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLN 74 (used in VBP-400)

[0589] NFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKA DYEKHKVYACEVTHQGLSSPVTKSFNRGEC EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLE WVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAV HER2 light chain II

[0590] YYCSRWGGDGFYAMDYWGQGTLVTVSSASVAAPSVFIFPPSDEQLK 75 (used in VBP-500)

[0591] SGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0592]

[0593] Amino acid sequences of certain other parts of the antibodies generated and utilized in the present invention include the following.

[0594] Table 9:

[0595] Description Amino acid sequence SEQ ID No.

[0596] RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL

[0597] Light chain constant

[0598] QSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLS 54 domain (K)

[0599] SPVTKSFNRGEC GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSP

[0600] Light chain constant

[0601] VKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGST 55 domain (A)

[0602] VEKTVAPTECS DKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD CH2 WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTK 13 NQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLV SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0603] Heavy chain knob ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS

[0604] (CHl-hinge-CH2- GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ.TYICNVNHKPSNTKVDK 56 CH3) KVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTC

[0605]

[0606] VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPC RDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ.TYICNVNHKPSNTKVDK Heavy chain hole KVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTC

[0607] (CHl-hinge-CH2- VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT 57 CH3) VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPS RDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK DKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS

[0608] Heavy chain knob HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

[0609] empty (hinge-CH2- WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTK 58 CH3) NQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG DKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS

[0610] Heavy chain hole HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

[0611] empty (hinge-CH2- WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTK 59 CH3) NQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLV SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0612] 2X(G4S) linker GGGGSGGGGS 61 3X(G4S) linker GGGGSGGGGSGGGGS 11 4X(G4S) linker GGGGSGGGGSGGGGSGGGGS 12 5X(G4S) linker GGGGSGGGGSGGGGSGGGGSGGGGS 64

[0613]

[0614] Nucleic acids, vectors and host cells

[0615] In certain embodiments, the present disclosure provides a nucleic acid molecule or a nucleic acid composition comprising a nucleic acid sequence or a plurality of nucleic acid sequences encoding the molecules of the present disclosure.

[0616] In certain embodiments, the present disclosure provides a nucleic acid molecule or a nucleic acid composition comprising a molecule comprisinga) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and

[0617] b) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,

[0618] wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein

[0619] i) said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 with an amino acid substitution at position L45 (according Chothia) and a variable light chain of SEQ ID No.2,

[0620] ii) the variable light chain of said first antigen binding domain has a mutation at position 86 (according to Chothia), preferably wherein said mutation is a mutation to alanine, or ill) in said first antigen binding domain at least the VH domain and VL domain are replaced by each other. In certain embodiments, said variable heavy chain of the third antigen binding domain and said variable light chain of the third antigen binding domain associate with each other. In certain embodiments, said third antigen binding domain comprises a variable heavy chain of SEQ ID No.

[0621] 76 or 77 and a variable light chain of SEQ ID No. 2. In certain embodiments, the variable light chain of said first antigen binding domain has a mutation to alanine at position 86 (according to Chothia), and said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2. In certain embodiments, the variable light chain of said first antigen binding domain has a mutation to serine at position 86 (according to Chothia), and said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2. In certain embodiments, the variable light chain of said first antigen binding domain has a mutation to proline at position 86 (according to Chothia), and said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2. In certain embodiments, the variable light chain of said first antigen binding domain has a mutation to glutamine at position 86 (according to Chothia), and said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2. In certain embodiments, the variable light chain of said first antigen binding domain has a mutation to arginine at position 86 (according to Chothia), and said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2. In certain embodiments, the variable light chain of said first antigen binding domain has a mutation to glutamic acid at position 86 (according to Chothia), and said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable lightchain of SEQ ID No. 2. In certain embodiments, in said first antigen binding domain the variable light chain is replaced by the variable heavy chain of said first antigen binding domain and the constant light chain domain CL is replaced by the constant heavy chain domain CHI of said first antigen binding domain, and the variable heavy chain is replaced by the variable light chain first of said antigen binding domain and the constant heavy chain domain CHI is replaced by the constant light chain domain CL of said first antigen binding domain. In certain embodiments, in said first antigen binding domain the variable light chain is replaced by the variable heavy chain of said first antigen binding domain, and the variable heavy chain is replaced by the variable light chain first of said antigen binding domain. In certain embodiments, said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2.

[0622] In certain embodiments, the present disclosure provides a nucleic acid molecule or a nucleic acid composition comprising a half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,

[0623] wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein

[0624] i) said variable heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 with an amino acid substitution at position L45 (according Chothia), ii) the variable light chain of said first antigen binding domain has a mutation to alanine at position 86 (according to Chothia), or

[0625] ill) in said first antigen binding domain at least the VH domain and VL domain are replaced by each other. In certain embodiments, said heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 76 or 77. In certain embodiments, the variable light chain of said first antigen binding domain has a mutation to alanine at position 86 (according to Chothia) and wherein said heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80. In certain embodiments, in said first antigen binding domain the variable light chain is replaced by the variable heavy chain of said first antigen binding domain and the constant light chain domain CL is replaced by the constant heavy chain domain CHI of said first antigen binding domain, and the variable heavy chain is replaced by the variable light chain first of said antigen binding domain and the constant heavy chain domain CHI is replaced by the constant light chain domain CL of said first antigen binding domain. In certain embodiments, in said first antigen binding domain the variable light chain is replaced by the variable heavy chain of said first antigen binding domain, and the variable heavy chain is replaced by the variable lightchain first of said antigen binding domain. In certain embodiments, said heavy chain of said third antigen binding domain comprises a variable heavy chain of SEQ. ID No. 1 or 80.

[0626] In certain embodiments, the present disclosure provides a vector or a plurality of vectors comprising a nucleic acid composition comprising a nucleic acid molecule or a nucleic acid composition as defined herein above.

[0627] In certain embodiments, the present disclosure provides a host cell comprising a vector composition comprising a vector or a plurality of vectors comprising a nucleic acid molecule or a nucleic acid composition as defined herein above.

[0628] In certain embodiments, the host cell is an isolated host cell. In certain embodiments, said host cell is a mammalian cell. In certain embodiments, said mammalian cell is a human cell. In certain embodiments, said mammalian cell is a CHO cell. In certain embodiments, said cell is a HEK cell. In certain embodiments, said cell is a PERC.6 cell. In certain embodiments, said cell is a HKB11 cell. The skilled artisan will realize that the nucleic acid sequence or the plurality of nucleic acid sequences encoding the heavy and / or light chain of an antibody or antibody fragment of the present disclosure can be cloned into different vectors or into the same vector.

[0629] The vectors can be introduced into the appropriate host cells such as prokaryotic (e.g., bacterial) or eukaryotic (e.g., yeast or mammalian) cells by methods well known in the art (see e.g., "Current Protocol in Molecular Biology", Ausubel et al. (eds.), Greene Publishing Assoc and John Wiley Interscience, New York, 1989 and 1992). Numerous cloning vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of choice. The gene can be placed under the control of a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator (collectively referred to herein as "control" elements), so that the nucleic acid sequence encoding the desired protein is transcribed into RNA in the host cell transformed by a vector containing this expression construction. The coding sequence may or may not contain a signal peptide or leader sequence. Upon expression in host cells, the antibodies or antibody fragments of the present disclosure are obtained. These steps can be achieved in different ways, as will be known by the person skilled in the art. In general, such steps typically include transforming or transfecting a suitable host cell with a nucleic acid composition or vector composition or an infectious particle, which encodes the antibody, or antibody fragments. Further, such steps typically include culturing said host cells under conditions suitable for the proliferation (multiplication, growth) of said host cells and a culturing step under conditions suitable for the production (expression, synthesis) of the encoded antibody or antibody fragment. The culturing of host cells under conditions suitable for proliferation or expression is typically accomplished in the presence of media comprising components suitable for cell growth orinduction of expression. In particular, embodiments, the methods for the production of the antibodies or antibody fragments of the present disclosure further comprise the step of isolating and purifying the produced antibody or antibody fragment from the host cells or medium. If the expression system secretes the protein into growth media, the protein can be purified directly from the media. If the protein is not secreted, it is isolated from cell lysates or recovered from the cell membrane fraction. The selection of the appropriate growth conditions and recovery methods are within the skill of the art. The antibody or antibody fragment of the present disclosure can then be purified by a number of techniques as known to the person skilled in the art.

[0630] Therapeutic use

[0631] The molecules and half-molecules of the present disclosure, or pharmaceutical compositions incorporating the same, can be used for the treatment of various diseases and disorders.

[0632] In certain embodiments, the present disclosure provides the molecules and half-molecules as defined herein for use in medicine. The therapeutic efficacy of the present disclosure can be tailored to specific indications based on its mechanism of action, targeting capabilities, and therapeutic activity.

[0633] In certain embodiments, the present disclosure provides the molecules and half-molecules as defined herein for use in the treatment of cancer .In certain embodiments, said cancer is selected from a solid cancer or a hematologic cancer.

[0634] In certain embodiments, said cancer is a solid cancer. In certain embodiments, said solid cancer is selected from a carcinoma, a sarcoma or another solid tumors. In certain embodiments, said solid cancer is a carcinoma. In certain embodiments, said carcinoma is selected from breast cancer, colorectal cancer, lung cancer (including non-small cell lung cancer and small cell lung cancer), prostate cancer, gastric cancer, and pancreatic cancer. In certain embodiments, said solid cancer is a sarcoma. In certain embodiments, said sarcoma is selected from osteosarcoma, leiomyosarcoma, liposarcoma, and Ewing's sarcoma. In certain embodiments, said solid cancer is another solid cancer. In certain embodiments, said other solid tumor is selected from melanoma, glioblastoma multiforme, hepatocellular carcinoma, and renal cell carcinoma.

[0635] In certain embodiments, said cancer is a hematologic cancer. In certain embodiments, said hematologic cancer is selected from a leukemia, a lymphoma and a plasma cell disorder. In certain embodiments, said hematologic cancer is leukemia. In certain embodiments, said leukemia is selected from acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). In certain embodiments, said hematologic canceris lymphoma. In certain embodiments, said lymphoma is selected from non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma (DLBCL). In certain embodiments, said hematologic cancer is a plasma cell disorder. In certain embodiments, said plasma cell disorder is selected from multiple myeloma and Waldenstrom's macroglobulinemia. In certain embodiments, the present disclosure provides the molecules and half-molecules as defined herein for use in the treatment of an inflammatory disease. In certain embodiments, said inflammatory disease is selected from a rheumatologic condition, a dermatologic condition, and a gastrointestinal condition. In certain embodiments, said inflammatory disease is a rheumatologic condition. In certain embodiments, said rheumatologic condition is selected from rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. In certain embodiments, said inflammatory disease is a dermatologic condition. In certain embodiments, said dermatologic condition is selected from psoriasis and hidradenitis suppurativa. In certain embodiments, said inflammatory disease is a gastrointestinal condition. In certain embodiments, said gastrointestinal condition is inflammatory bowel disease. In certain embodiments, said gastrointestinal condition is Crohn's disease. In certain embodiments, said gastrointestinal condition is ulcerative colitis.

[0636] In certain embodiments, the present disclosure provides the molecules and half-molecules as defined herein for use in the treatment of an autoimmune disease. In certain embodiments, said autoimmune disease is selected from a systemic autoimmune disease and an organ-specific autoimmune disease. In certain embodiments, said autoimmune disease is a systemic autoimmune disease. In certain embodiments, said systemic autoimmune disease is selected from systemic lupus erythematosus (SLE) and systemic sclerosis. In certain embodiments, said autoimmune disease is an organ-specific autoimmune disease. In certain embodiments, said organ-specific autoimmune disease mis selected from type 1 diabetes, autoimmune thyroiditis (e.g., Hashimoto's thyroiditis and Graves' disease), and multiple sclerosis.

[0637] In certain embodiments, the present disclosure provides the molecules and half-molecules as defined herein for use in the treatment of diseases associated with aberrant immune or oncologic processes. Examples include but are not limited to neuroblastoma, retinoblastoma, and rare autoinflammatory syndromes such as familial Mediterranean fever and periodic fever syndromes.

[0638] In certain embodiments, the present disclosure provides a method for the treatment of a disease comprising administering to a patient a molecule or half-molecule as disclosed herein.

[0639] In certain embodiments, the present disclosure provides a method for the prevention of a disease comprising administering to a patient a molecule or half-molecule as disclosed herein.In an embodiment, the present disclosure provides a pharmaceutical composition comprising a molecule or half-molecule as disclosed herein and a pharmaceutically acceptable carrier or excipient.

[0640] Methods of improving therapeutic molecules

[0641] In certain embodiments the present disclosure provide a method of improving a molecule comprising

[0642] a) providing a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain, wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0643] b) substituting the amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain to a lysine, valine, threonine, asparagine, aspartic acid, cysteine, histidine, glycine, methionine, leucine, alanine, serine, proline, glutamine, arginine or glutamic acid.

[0644] In certain embodiments the present disclosure provide a method of improving a molecule comprising

[0645] a) providing a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain, wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and

[0646] b) substituting the amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain to a methionine, leucine, alanine, serine, proline, glutamine, arginine or glutamic acid. In certain embodiments, said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to methionine. In certain embodiments, said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to leucine. In certain embodiments, said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to alanine. In certain embodiments, said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to serine. In certain embodiments, said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to proline.In certain embodiments, said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to glutamine. In certain embodiments, said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to arginine. In certain embodiments, said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to glutamic acid. In certain embodiments, said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to lysine. In certain embodiments, said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to valine. In certain embodiments, said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to threonine. In certain embodiments, said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to asparagine. In certain embodiments, said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to aspartic acid. In certain embodiments, said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to cysteine. In certain embodiments, said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to histidine. In certain embodiments, said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to glycine. In certain embodiments, said variable light chain of the first antigen binding domain provided in step a) has a tyrosine at position 86 (according to Chothia).

[0647] EXAMPLES

[0648] Example 1: Design and generation of mutated CD3 binding domains orTAA binding domains with reduced propensity for association of an additional free LC

[0649] The BiTAC precursor molecules that carry the UCHT or UCHT Prime variable heavy chain are affected by the non-covalent association of an additional free light chain during expression as illustrated in Figure 2A. The light chain (variable light and constant light) that is intended to form the tumor targeting domain (Fab) binds via its variable domain to the UCHT variable heavy chain. Figure 2B shows a CE-SDS profile under non-reduced condition of a wild-type BiTAC with an additional peak (black arrow) that represents the size of the associated Variable light chain. Even the titration of plasmid ratios (e.g.decrease the amount of plasmid encoding the light chain) during the triple transfection did not significantly decrease the number of side species.

[0650] The approach taken herein is based on the initial finding that the molecules of the present disclosure had a higher ratio of correct chain assembly when the variable heavy chain of antibody UCHT was mutated at certain positions, such as position L45. A semi rational approach was therefore used in order to identify mutation sites in the variable heavy chain of antibody UCHT or the variable light chain of the first antigen binding domain with a reduced propensity for association of the variable light chain of the first antigen binding domain to the variable heavy chain of antibody UCHT. In particular the region around position 45 of the variable heavy chain antibody UCHT, and the corresponding positions Y86 and Y87 on the variable light chain of the first antigen binding domain were investigated, since it was speculated certain mutations may be helpful to avoid wrong light chain pairing.

[0651] The following tables show all mutations tested in order to abolish the association light chain of the first antigen binding domain to the variable heavy chain of antibody UCHT (mutations in the variable heavy chain of antibody UCHT are shown in Table 10, mutations in the light chain of the first antigen binding domain in Table 11, nomenclature of the mutation sites according to Chothia). Indicated in each table are the utilized first antigen binding domains and the relative amount of BiTAC precursors (percentage) affected by the association of the light chain of the first antigen binding domain to the variable heavy chain of antibody UCHT, as measured from the cleanest preparative SEC fraction by CE-SDS

[0652] Table 10: UCHT-VH mutations

[0653] Mutation Target binder % VJ / LC association

[0654] V37A CD38 52.9

[0655] Q39A CD38 26.5

[0656] L45A CD38 0

[0657] G96E CD38 87.7

[0658] G96S CD38 48.7

[0659] V37M HER2 62.5

[0660] V37F HER2 35.8

[0661] G44E HER2 58.4

[0662] G44W HER2 102.3

[0663] L45W HER2 32.7

[0664] L45R HER2 6.1

[0665] W47G HER2 65.0

[0666] S95V HER2 60.0

[0667] G96D HER2 54.7

[0668] G96Q HER2 52.1G96R HER2 52.4

[0669] Table 11: TAA-LC mutations (where two values are shown, results of independent experiments are indicated)

[0670] Mutation % VJ / LC association

[0671] A43P CD38 106.3

[0672] Y86A CD38 3.7

[0673] Y87A CD38 67.7

[0674] F98A CD38 0

[0675] A43P HER2 100.9

[0676] Y86A HER2 7.2 / 0

[0677] Y87A HER2 93.1

[0678] The most effective mutations carried a L45A or a L45R mutation in the variable heavy chain of antibody UCHT, or a Y86A mutation in the variable light chain of the first antigen binding domains. The latter was independent of the first antigen binding domains tested.

[0679] Amino acid sequences of certain improved derivatives are as follows (CDRs according to Chothia). Table 12:

[0680] VH of UCHT with L45A

[0681] EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGK VH GAEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLR SEQ ID No. 76 AEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS HCDR1 GYSFTGY SEQ ID No. 3 HCDR2 NPYKGV SEQ ID No. 4 HCDR3 SGYYGDSDWYFDV SEQ ID No. 5 VH of UCHT with L45R

[0682] EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGK VH GREWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLR SEQ ID No. 77 AEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS HCDR1 GYSFTGY SEQ ID No. 3 HCDR2 NPYKGV SEQ ID No. 4 HCDR3 SGYYGDSDWYFDV SEQ ID No. 5

[0683]

[0684] VL of HER2 withY86A

[0685] DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKA VL PKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATAYCQQ SEQ ID No. 78 HYTTPPTFGQGTKVEIK LCDR1 RASQDVNTAVA SEQ ID No. 19 LCDR2 SAS FLYS SEQ ID No. 20 LCDR3 QQHYTTPPT SEQ ID No. 21 VL of CD38 with Y86A

[0686] DIELTQPPSVSVAPGQ.TARISCSGDNIGNKYVSWYQQKPGQAPV

[0687] VL VVIYGDNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADAYCSS SEQ ID No. 79 YDSSYFVFGGGTKLTVL LCDR1 SGDNIGNKYVS SEQ ID No. 39 LCDR2 GDNNRPS SEQ ID No. 40 LCDR3 SSYDSSYFV SEQ ID No. 41

[0688]

[0689] Example 2: Generation of BiTAC precursor molecules with reduced LC impurity

[0690] Example 2.1 Construction of expression plasmids for the BiTAC precursors

[0691] The BiTAC precursor constructs disclosed herein were produced by transiently transfecting human embryonic kidney (HEK 293) cells. For expressing a specific gene or protein, such as a full-length antibody heavy chain, a full-length antibody light chain, or a full-length heavy chain with an additional domain (e.g., a variable domain of an immunoglobulin heavy or light chain at its C-terminus), a transcription unit was designed with the following functional elements:

[0692] - The immediate early enhancer and promoter from the human cytomegalovirus (P-CMV) - A human heavy chain immunoglobulin 5'-untranslated region (5'UTR)

[0693] - A murine immunoglobulin heavy chain signal sequence

[0694] - The target gene or protein to be expressed

[0695] - WPRE (Woodchuck posttranscriptional regulatory element) downstream of the cloning site to improve protein expression.In addition to the expression cassette containing the target gene, the basic mammalian expression plasmid also included a pUC origin and a beta-lactamase gene.

[0696] Genes encoding the antibody heavy chain, including C-terminal fusion constructs, were engineered to contain a complete and functional antibody heavy chain sequence followed by an additional variable (V) domain, either V-heavy or V-light. This was achieved by fusing a DNA sequence encoding the respective V domain (either VH or VL) to the C-terminus of the CH3 domain of a human IgG molecule. These fusions were constructed with a flexible 4X(G4S)-linker (SEQ. ID No. 12), resulting in configurations, such as VH-CHl-hinge-CH2-CH3-linker-VH, VH-CHl-hinge-CH2-CH3-linker-VL or VL-CHl-hinge-CH2-CH3-VH (CrossMab format).

[0697] Recombinant antibody molecules containing one VH or VL domain at the C-termini of one CH3 domain were produced using the knob-into-hole technology, enabling efficient pairing of the individual chains to generate a BiTAC precursor.

[0698] Genes encoding a complete and functional antibody light chain were constructed by assembling DNA fragments that code for the relevant sequence elements (VL-CL or VH-CL (CrossMab format)). The transcription unit for the antibody light chain fragment contained the following functional elements: - The immediate early enhancer and promoter from human cytomegalovirus (P-CMV)

[0699] - A 5'-untranslated region (5'UTR) from human heavy chain immunoglobulin for enhanced translation

[0700] - A murine immunoglobulin heavy chain signal sequence for secretion

[0701] - The nucleic acid sequence encoding the antibody light chain (VL-CL)

[0702] In addition to the expression cassette containing the target gene, the basic mammalian expression plasmid also included a pUC origin and a beta-lactamase gene.

[0703] Example 2.2 Expression of the BiTAC precursor molecules

[0704] The BiTAC precursor molecules were generated in transiently transfected HEK293 cells (human embryonic kidney cell line 293-derived) cultivated in Expi293™ Expression Medium (Gibco™, #A1435102). For transfection PEI MAX® Transfection Reagent (Polysciences Europe GmbH, # 24765) was used. The respective BiTAC precursor heavy- and light chain molecules as described above were expressed from individual expression plasmids. All used plasmids were synthesized by Invitrogen GeneArt services (Thermo Fisher Scientific Inc.). Transfections were performed as specified in the manufacturer's instructions. Immunoglobulin-containing cell culture supernatants were harvested five days after transfection (see also Meissner, P. et al., Biotechnol. Bioeng. 75 (2001) 197-203).BiTACs were purified by a MabSelect SuRe (Cytiva, #11003494) (Affinity Chromatography) and followed by Superdex 200 (Cytiva, #28990944) (Size Exclusion Chromatography). The constructs generated are summarized in the following Table.

[0705] Table 13:

[0706] Molecule CD3 binder Mutation Target Target binder SEQID No.s domain CD3 binder mutation (domain)

[0707] binder

[0708] VBP-100 VH WT CD38 WT 60; 69 VBP-101 VH WT CD38 Y86A (VL) 60; 70 VBP-102 VH L45A CD38 WT 62; 69 VBP-200 VH WT HER2 WT 63; 71 VBP-201 VH WT HER2 Y86A (VL) 63; 72 VBP-202 VH L45R HER2 WT 65: 71 VBP-300 VL WT SLAMF7 WT 66; 73 VBP-400 VL WT EpCAM WT 67; 74 VBP-500 VH WT HER2 WT 68; 75

[0709]

[0710] The purification yield of BiTAC precursors is summarized in the following Table.

[0711] Table 14 (where two values are shown, results of independent experiments are indicated):

[0712] Molecule % VJ / LC association in Volumetric yield

[0713] cleanest SEC fraction [mg / L]

[0714] VBP-100 83.6 5.7

[0715] VBP-101 3.7 11.0

[0716] VBP-102 0 58.6

[0717] VBP-200 77.7 6.0

[0718] VBP-201 7.2 / 0 18.2

[0719] VBP-202 6.1 34.0

[0720] VBP-300 0 57.3

[0721] VBP-400 0 82.5

[0722] VBP-500 0 28.3

[0723]

[0724] As can be seen, the introduced mutations into either the UCHT Prime VH or the VL of the of the first antigen binding domain led to a significant decrease of LC association of the VL of the of the first antigen binding domain to the VH of antibody UCHT Prime and resulted in increased volumetric yieldsof the desired monomer. A reduced association was also observed for construct VBP-500 which carried the wildtype sequences, but which is arranged in the CrossMab format.

[0725] Figure 4A shows the CE-SDS profile of the HER2-targeting wildtype BiTAC with associated light chain present (black arrow). Figure 4B and Figure 5 show the impact of Y86A and L45A respectively by a significantly reduced presence of the additional light chain. Figure 6A shows the CE-SDS profile of the CD38-targeting WT BiTAC with associated light chain present (black arrow). Figure 6B and Figure 7 show the impact of Y86A and L45R respectively by a significantly reduced presence of the additional light chain.

[0726] Figure 13A shows the CE-SDS profile of the HER2-targeting WT BiTAC with associated light chain present (black arrow). Figure 13B shows the impact of the domain reorganization as illustrated in Figure 12 (right) by a significantly reduced presence of the additional light chain.

[0727] Figure 15 shows the CE-SDS profile of the HER2-targeting wildtype BiTAC containing the split variable heavy domain of the anti CD3 clone SP34. Similar to the UCHT-1 derived BiTAC precursor, this alternative CD3 domain is prone to have an associated LC present (black arrow). Figure 15B shows the impact of Y86A by a significantly reduced presence of the additional light chain.

[0728] Example 2.3 Evaluation of different substitutions at position 86 of the variable light chain of the first antigen binding domain

[0729] To understand why the Y86A mutation disrupts LC association in BiTACs containing UCHT-VH, the HER2-UCHT-VH BiTAC construct was engineered with different amino acid substitutions at position 86. Each variant was expressed independently, and the extent of LC association was assessed by measuring the relative amount of free LC using CE-SDS. Comparative analysis of free LC levels across variants was used as a surrogate readout for VH-LC pairing efficiency. Additionally, cell binding was assessed to determine the influence of mutation on TAA binder integrity.

[0730] All variants were transiently expressed under the same conditions as described above, as were measurements of cell binding and flow cytometry. The relative amount of free light chains present in each sample was determined using CE-SDS under native conditions. Samples were prepared according to standard CE-SDS protocols and free LC peaks were quantified and compared across variants.

[0731] The following additional variants of the variable light chain of HER2 with single-amino acid substitutions position 86 were generated and tested:

[0732] ODescription Amino acid sequence SEQID No.

[0733] DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGK HER2 - VL APKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFA 15

[0734] TYYCQQHYTTPPTFGQGTKVEIK DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGK

[0735] Y86A APKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFA 78

[0736] TAYCQQHYTTPPTFGQGTKVEIK DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGK

[0737] Y86E APKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFA 89

[0738] TEYCQQHYTTPPTFGQGTKVEIK DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGK

[0739] Y86F APKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFA 90

[0740] TEYCQQHYTTPPTFGQGTKVEIK DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGK

[0741] Y86L APKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFA 91

[0742] TLYCQQHYTTPPTFGQGTKVEIK DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGK

[0743] Y86M APKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFA 92

[0744] TMYCQQHYTTPPTFGQGTKVEIK DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGK

[0745] Y86P APKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFA 93

[0746] TEYCQQHYTTPPTFGQGTKVEIK DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGK

[0747] Y86Q. APKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFA 94

[0748] TQYCQQHYTTPPTFGQGTKVEIK DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGK

[0749] Y86R APKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFA 95

[0750] TRYCQQHYTTPPTFGQGTKVEIK DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGK

[0751] Y86S APKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFA 96

[0752] TSYCQQHYTTPPTFGQGTKVEIK DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGK

[0753] Y86W APKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFA 97

[0754] TWYCQQHYTTPPTFGQGTKVEIK

[0755]

[0756] Purification yield of BiTAC precursors are summarized in the following Table:

[0757] Molecule % VJ / LC association in Volumetric yield

[0758] cleanest SEC fraction [mg / L]

[0759] HER2 -VL 92.6 141

[0760] Y86A 0 20.4

[0761] Y86E 0 3.5

[0762] Y86F 96.07 120.3

[0763] Y86L 42.67 48.5

[0764] Y86M 71 60

[0765] Y86P 0 34.1

[0766] Y86Q. 1.26 25.12

[0767] Y86R 0 3

[0768] Y86S 1.53 30

[0769] Y86W 88.27 68.8

[0770]

[0771] Substitutions introducing small or polar residues at position 86 (A, S, P, Q) consistently resulted in no detectable LC association. Similarly, charged residues (either positively charged (R) or negatively charged (E)) likewise result in no detectable LC association.

[0772] In contrast, large aromatic residues demonstrated a strong capacity to promote LC association. Replacement of Tyr (Y) with Trp (W) or Phe (F) resulted in clear LC association, comparable to or exceeding that observed for the wild-type tyrosine residue.

[0773] Hydrophobic, but non-aromatic substitutions showed intermediate effects. Methionine (M) and leucine (L) substitutions resulted in reduced but detectable LC association, suggesting partial compatibility. These residues provide hydrophobic surface area but lack the rigid aromatic ring structure present in Tyr, Phe, and Trp. Together, these results suggest that hydrophobicity alone is insufficient to fully support LC association without accompanying aromaticity and size.

[0774] Ranking of amino acids by hydrophobicity and side-chain volume revealed a strong correlation between large side-chain volume and high hydrophobicity with LC association. Trp, Tyr, and Phe, which exhibit the largest side-chain volumes and high hydrophobicity, consistently supported LC association.In contrast, residues with small volumes (G, A, S) or polar characteristics showed no LC association despite moderate hydrophobicity in some cases. See also Figure 16.

[0775] Collectively, these results demonstrate that large hydrophobic and aromatic residues at position 86 of the of the variable light chain of the first antigen binding domain are critical for LC association. Substitution of tyrosine with smaller, polar, or charged residues disrupts this interaction, explaining why the Y86A mutation effectively prevents LC association. These findings suggest that residue 86 plays a structural role, likely contributing to a hydrophobic / aromatic interface essential for stabilizing VH-LC pairing:

[0776] Strong LC association: W, F, Y

[0777] Reduced LC association: M, L

[0778] No LC association: A, S, P, Q, R, E

[0779] Based on these data, also the following amino acids should lead to a reduced LC association: K and V. Furthermore, the following amino acids should lead to no LC association: T, N, D, C, H and G.

[0780] Example 2.4 Conservation and structural role of residue 86 in the antibody variable light domain

[0781] Residue 86 of the variable light (VL) domain is highly conserved across antibody sequences, indicating a strong evolutionary constraint at this position. Analyses using the abYsis antibody database distribution tool showed that Chothia position L86 is dominated by a single amino acid residue, tyrosine, with alternative residues occurring only at very low frequencies across a large, non-redundant set of light-chain sequences (http: / / www.abysis.org / abysis / searches / distributions / distributions.cgi). This level of conservation is characteristic of framework residues that play essential structural roles rather than contributing directly to antigen recognition. See Figure 18.

[0782] Structural and conformational analyses of antibody variable domains further support the functional importance of conserved framework positions proximal to CDRs. Large-scale clustering of over 300 non-redundant antibody structures demonstrated that framework architecture and CDR conformations are tightly coupled, with specific framework positions constraining allowable loop geometries and domain packing (J Mol Biol (2011) 406: 228-56). In this context, conserved framework residues such as position 86 help define the structural environment that supports canonical CDR conformations and stable domain assembly.Complementary sequence-based analyses spanning hundreds of heavy- and light-chain sequences from multiple species also that framework residues exhibit significantly higher conservation than CDR residues, particularly at positions implicated in domain folding and inter-domain interactions (Molecular Immunology (2016) 70:63-71). These studies highlight aromatic and hydrophobic framework residues as key determinants of immunoglobulin domain stability, suggesting that substitutions at conserved framework positions can have disproportionate effects on domain pairing and assembly.

[0783] Consistent with this view, comparative analyses of VL framework regions across germline families reveal that invariant or near-invariant residues within framework 3 (the region encompassing position 86) are spatially positioned to influence both intradomain stability and VH-VL interface formation (Proteins (2009) 76: 99-114).

[0784] Taken together, database-level conservation (abYsis), large-scale structural clustering, and comparative framework analyses converge on the conclusion that position 86 represents a highly conserved framework residue critical for immunoglobulin domain integrity. About 99.2% of all antibodies carry a tyrosine residue at position 86 of the variable light chain. Mutation of residue Y86, strongly perturbs VH-VL association by disrupting conserved framework interactions, rather than altering antigen-binding specificity. This framework-driven mechanism explains the robust and binder-independent effects of Y86Aon light-chain association observed across multiple BiTAC formats.

[0785] Example 3: Functional characterization of BiTAC precursor molecules

[0786] Figure 1 A schematically illustrates two exemplary BiTAC precursor molecules that are either directed against TAA1 or TAA2, each carrying one half of the split anti CD3 Fv, namely VH or VL. Figure IB illustrates the target-dependent complementation of an active CD3 binder on the surface of TAA1 and TAA2-expressing target cells. Thereby, CD3+ T cells are crosslinked, activated and the effector function (T cell dependent cytotoxicity (TDCC)) is induced.

[0787] Example 3.1 Methods

[0788] Binding of BiTACs to target cellsSK-BR-3 cells or MM. IS cells were resuspended in cold FACS buffer (PBS + 0.5% BSA) to a final density of lxlOA6 c / ml. BiTACs and a human IgG Isotype control antibody (R&D Systems, #MAB002) were serially diluted (final concentrations: 0.005 -400 nM) and added to the cells. After 60 min incubation on ice, the cells were washed three times in FACS buffer. After washing, the cells were resuspended in 100 pl FACS buffer containing secondary antibody (Goat a-hu lgG-AF488, Invitrogen #A32723, 2 pg / ml) and incubated 30 min on ice in the dark. The cells were then washed three times in FACS buffer and resuspended in 200 pl FACS buffer.

[0789] Flow Cytometry was performed by standard methods using a FACSymphony A3 (BD Biosciences) and an HTS plate-handling system. Data was analyzed using FlowJo Software version 10.8.1 (Tree Star Inc.), Microsoft Excel (Microsoft 365 Apps for Business, 2024), and GraphPad Prism version 10.2.3 (Graphpad Software, Inc.).

[0790] Cytotoxicity assay

[0791] As target cells either SK-BR-3 or MM. IS cells were used.

[0792] SK-BR-3 cells were detached using trypsin, washed once with PBS and resuspended in culture medium containing 10% FBS. lxl0A4 cells per well were seeded into a 96-well flat-bottom cell culture plate (Th Geyer) and incubated for 24h at 37°C and 5% CO2. The co-culture assay was set up the next day in RPMI 1640 (ATCC modification) + 5% FBS. To do so, purified human CD3+ T-cells (Isolated with EasySep Human T-cell Isolation Kit (STEMCELLTechnologies #17951) were added to the assay plate at an effector cell: target cell (E:T) ratio of 10:1.

[0793] Antibodies were diluted in RPMI 1640 (ATCC modification) + 5% FBS and added to the assay plate in duplicates at the indicated concentrations. The assay plates were incubated for 48h at 37°C and 5% CO2. Cytotoxic activity was assessed from supernatants using the Cytotoxicity Detection Kit (LDH) (Roche, #11644793001) according to the manufacturer's manual. Absorbance measurements were performed using a Spark Microplate reader (Tecan).

[0794] The percentage of cell-mediated cytotoxicity was calculated considering an effector cell control, target cell control and 100% killing control (Triton-X treated target cells) as stated in the manufacturer's protocol.

[0795] (Sample value - effector cell control)-target cell control Cytotoxicity [%] 100% killing control-target cell controlCell viability in % was calculated from the Cytotoxicity values and normalized to a 100% alive control (target + effector cells). More precisely, the following formula was applied:

[0796] (100 / (Viability "target + effector cells")

[0797] Cell viability [%] =

[0798] Viability "sample"

[0799] MM. IS cells were labeled with 1 pM CFSE (Invitrogen; #C34554) and resuspended in RPMI 1640 (ATCC modification) + 10% FBS. 2xlOA4 cells per well were seeded into a 96-well round-bottom plate (Thermo Fisher Scientific) and purified human CD3+ T cells (Isolated with EasySep Human T-cell Isolation Kit (STEMCELL Technologies #17951)) were added at an effector cell: target cell (E:T) ratio of 5:1.

[0800] Antibodies were diluted in RPMI 1640 (ATCC modification) + 10% FBS and added to the assay plate in duplicates at the indicated concentrations. The assay plates were incubated for 24h at 37°C and 5% CO2.

[0801] Next, live and dead cells were collected and resuspended in FACS buffer (PBS + 0.5% BSA) containing 0.75 pM DRAQ7 (BioStatus #DR71000).

[0802] Flow Cytometry was performed by standard methods using a FACSymphony A3 (BD Biosciences) and an HTS plate-handling system.

[0803] To calculate the cell viability the number of target cells was counted by gating on CFSE+ cells, and the number of live target cells was counted by gating on CFSE+ DRAQ7- cells. From there the % of cell viability was calculated as follows:

[0804] number of CFSE+DRAQ7 cells

[0805] Cell Viability [%] =

[0806] number of CFSE+cells

[0807] Afterwards, the cell viability was normalized to a 100% alive control (target + effector cells). More precisely, the following formula was applied:

[0808] (100 / (Viability "target + effector cells'")

[0809] Cell viability [%] =

[0810] Viability "sample"For data analysis and visualization, Microsoft Excel (Microsoft 365 Apps for Business, 2024) and GraphPad Prism version 10.2.3 (Graphpad Software, Inc.) were used.

[0811] Example 3.2 Results

[0812] Example 3.2.1 Introducing mutations to abolish additional LC association does not affect cell binding

[0813] As shown in Figure 8 the introduction of the Y86A mutation in the VL of the target binders does not affect target cell binding. In Figure 8A the HER2-targeting WT BiTAC (VBP-200) binds to SK-BR-3 cells (HER2 positive) in a similar range as the respective Y86A version (VBP-201). In Figure 8B the CD38-targeting WT BiTAC (VBP-100) binds to MM. IS cells (CD38 positive) in a similar range as the respective Y86A version (VBP-101).

[0814] As shown in Figure 9 the introduction of the mutation at the L45A in the UCHT Prime VH does not affect target cell binding. In Figure 9A the HER2-targeting WT BiTAC (VBP-200) binds to SK-BR-3 cells (HER2 positive) in a similar range as the respective L45R version (VBP-202). In Figure 9B the CD38-targeting WT BiTAC (VBP-100) binds to MM. IS cells (CD38 positive) in a similar range as the respective L45A version (VBP-102).

[0815] Also the additional variants at position 86 of the light chain of the first antigen binding (see Example 2.3) did not change the binding characteristics of the HER2 binder. See Figure 17.

[0816] Example 3.2.2 Introducing mutations retains the cytotoxicity of BiTAC combinations in co-culturinq assays of target and T cells

[0817] To assess the impact of the introduced mutations on the BiTAC efficacy, co-culture assay including target and effector cells were performed. As schematically shown in Figure 1 BiTAC precursor molecules carrying the UCHT Prime VH were combined with the counterpart carrying the UCHT Prime VL. HER2-targeting BiTAC precursors were paired with EpCAM-targeting BiTAC precursors (VBP-400) and tested on SK-BR-3 cells (HER2 positive, EpCAM positive). CD38 BiTAC precursors were paired with SLAMF7 BiTAC precursors (VBP-300) and tested on MM. IS cells (CD38 positive, SLAMF7 positive).As shown in Figure 10 the introduction of the Y86A mutation in the VL of the target binders does not affect target cell killing. In Figure 10A the HER2-targeting WT BiTAC (VBP-200) induce cytotoxicity on SK-BR-3 cells in a similar range as the respective Y86A version (VBP-201) when combined with the EpCAM-targeting counterpart (VBP-400). In Figure 10B the CD38-targeting WT BiTAC (VBP-100) induce cytotoxicity on MM. IS cells in a similar range as the respective Y86A version (VBP-101) when combined with the SLAMF7-targeting counterpart (VBP-300).

[0818] As shown in Figure 11 the introduction of the mutation at the L45 position in the VL of the target binders does not affect target cell killing. In Figure 11A the HER2-targeting WT BiTAC (VBP-200) induce cytotoxicity on SK-BR-3 cells in a similar range as the respective L45R version (VBP-202) when combined with the EpCAM-targeting counterpart (VBP-400). In Figure 11B the CD38-targeting WT BiTAC (VBP-100) induce cytotoxicity on MM. IS cells in a similar range as the respective L45A version (VBP-102) when combined with the SLAMF7-targeting counterpart (VBP-300).

[0819] Example 3.2.3 An alternative domain orientation in the targeting Fv retains both cell binding and cytotoxicity

[0820] The alternative domain orientation as depicted in Figure 12 (right) was tested in both cell binding and cytotoxicity assays. Figure 14A shows the binding of a HER2-targeted BiTAC precursor with either the WT (VBP-200) or alternative domain orientation (VBP-500) to SK-BR-3 cells. The cellular binding upon the domain re-organization is retained (VBP-500), however, slightly reduced compared to the WT domain order (VBP-200).

[0821] Figure 14B shows, that both BiTAC precursors either as WT (VBP-200) or the domain-reorganized version (VBP-500) show a similar cytotoxicity on SK-BR-3 cells when combined with the EpCAM-targeted BiTAC precursor counterpart (VBP-400).

[0822] Example 4: Functional characterization of BiTAC precursor molecules based on CD3 clone SP34

[0823] The previous experiments were repeated utilizing an alternative anti-CD3 binding domain, i.e. that of antibody SP34.

[0824] The heavy chain of antibody SP34 has the following amino acid sequence:Description Amino acid sequence SEQ ID No.

[0825] EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPG SP34 - VH KGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQ 82 MNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS SP34- HCDR1

[0826] GFTFNKY 83 (Chothia)

[0827] SP34- HCDR2

[0828] RSKYNNYA 84 (Chothia)

[0829] SP34 - HCDR3

[0830] HGNFGNSYI SYWAY 85 (Chothia)

[0831] SP34- HCDR1

[0832] KYAMN 86 (Kabat)

[0833] SP34- HCDR2

[0834] R I RS KYNN YAT Y YAD S VKD 87 (Kabat)

[0835] SP34- HCDR3

[0836] HGNFGNSYI SYWAY 85 (Kabat)

[0837]

[0838] Molecule VBP-700 contains the variable heavy wild type domain of SP34, as well as the variable heavy binding domain of the anti-HER2 binding domain of SEQ. ID No. 14. The full length amino acid sequence if the respective polypeptide is as follows:

[0839] EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGG PSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDE LTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSGGGGSGGGGSEVQLVESGGGL VQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFT I S RD D S KN T AY LQMNN L KT E D T AVY Y C VRH GN F GN S Y I S Y W AY W GQGTLVTVSS (SEQ ID No . 88)For the experiment the light chain of SEQ ID NO. 72, containing a Y86A mutation, and the heavy chain (hinge-CH2-CH3) of SEQ ID No. 59, containing the "hole"-mutations were used.

[0840] As for antibody UCHT1, also for antibody SP34, the introduction of the Y86A mutation in the light chain of the HER2 binder significantly reduced incorrect light chain association. See Figure 15. While the wild-type light chain showed an incorrect association of 28.8%, no incorrect association could be observed with a light chain carrying the Y86A mutation.

Claims

1. CLAIMS1. A molecule comprisinga) a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, andb) a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain,wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and wherein the variable light chain of said first antigen binding domain has a mutation at position 86 (according to Chothia).

2. A molecule according to claim 1, wherein the variable light chain of said first antigen binding domain has an amino acid at position 86 (according to Chothia) selected from methionine, leucine, lysine, valine, alanine, serine, proline, glutamine, arginine, glutamic acid, threonine, asparagine, aspartic acid, cysteine, histidine and glycine.

3. A molecule according to claim 1 or 2, wherein the variable light chain of said first antigen binding domain has an amino acid at position 86 (according to Chothia) selected from alanine, serine, proline, glutamine, arginine, glutamic acid, threonine, asparagine, aspartic acid, cysteine, histidine and glycine.4 A molecule according to any of claims 1-3 , wherein the variable light chain of said first antigen binding domain has an amino acid at position 86 (according to Chothia) selected from alanine, serine, proline, glutamine, arginine and glutamic acid.

5. A molecule according to any of claims 1-4, wherein the variable light chain of said first antigen binding domain has a mutation to alanine, serine, proline, glutamine, arginine or glutamic acid at position 86 (according to Chothia), andwherein said third antigen binding domain comprises a variable heavy chain of SEQ ID No. 1 or 80 and a variable light chain of SEQ ID No. 2.

6. A half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain,wherein said variable heavy chain of said third antigen binding domain is specific for cluster of differentiation 3 (CD3), and whereinthe variable light chain of said first antigen binding domain an amino acid at position 86 (according to Chothia) selected from methionine, leucine, lysine, valine, alanine, serine, proline, glutamine, arginine, glutamic acid, threonine, asparagine, aspartic acid, cysteine, histidine and glycine.

7. A half molecule according to claim 6, wherein the variable light chain of said first antigen binding domain has an amino acid at position 86 (according to Chothia) selected from alanine, serine, proline, glutamine, arginine, glutamic acid, threonine, asparagine, aspartic acid, cysteine, histidine and glycine.

8. A half molecule according to claim 6 or 7, wherein the variable light chain of said first antigen binding domain has an amino acid at position 86 (according to Chothia) selected from alanine, serine, proline, glutamine, arginine and glutamic acid.

9. A nucleic acid molecule or a nucleic acid composition comprising a nucleic acid sequence or a plurality of nucleic acid sequences encoding a molecule or a half-molecule according to any one of the preceding claims.

10. A molecule or a half-molecule according to any one of claims 1-8 for use in medicine, preferably wherein said used in medicine is the treatment of a cancer, an inflammatory disease or an autoimmune diseases.

11. A method of improving a molecule comprisinga) providing a first half-molecule comprising a first antigen binding domain and a variable heavy chain of a third antigen binding domain, and a second half-molecule comprising a second antigen binding domain and a variable light chain of a third antigen binding domain, wherein said third antigen binding domain is specific for cluster of differentiation 3 (CD3), andb) substituting the amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain to a methionine, leucine, lysine, valine, alanine, serine, proline, glutamine, arginine, glutamic acid, threonine, asparagine, aspartic acid, cysteine, histidine or glycine.

12. The method according to claim 11, wherein said amino acid at position 86 (according to Chothia) of the variable light chain of said first antigen binding domain is substituted to alanine, serine, proline, glutamine, arginine, glutamic acid, threonine, asparagine, aspartic acid, cysteine, histidine or glycine.

13. The method according to claim 11 or 12, wherein said variable light chain of the first antigen binding domain provided in step a) has a tyrosine at position 86 (according to Chothia).